,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,200,1,1,,444583,681,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6C3F1 mice,Other,,
1,256,1,1,,444583,681,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
2,357,2,1,,11111282,681,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
3,410,1,5,,11111282,681,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
4,411,2,1,,11111282,681,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
5,444,1,1,,11111282,681,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
6,445,3,1,,11111282,681,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
7,446,1,1,,11111282,681,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
8,447,1,1,,11111282,681,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
9,448,1,2,,11111282,681,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
10,450,1,2,,11111282,681,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
11,451,1,2,,11111282,681,Inconclusive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
12,526,1,1,,11111282,681,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
13,530,1,1,,11111282,681,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
14,584,1,3,,11111282,681,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
15,585,1,4,,11111282,681,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
16,587,1,5,,11111282,681,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
17,588,1,4,,11111282,681,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
18,589,1,3,,11111282,681,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
19,590,1,3,,11111282,681,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
20,591,1,4,,11111282,681,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
21,592,1,6,,11111282,681,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
22,593,1,4,,11111282,681,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
23,594,1,4,,11111282,681,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
24,595,1,3,,11111282,681,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
25,596,1,2,,11111282,681,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
26,597,1,3,,11111282,681,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
27,603,1,2,,11111282,681,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
28,605,1,2,,11111282,681,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
29,607,1,3,,11111282,681,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
30,662,1,1,,11111282,681,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
31,875,1,2,,11111282,681,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
32,875,1,2,,26750067,681,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
33,879,1,2,,11111282,681,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
34,879,1,2,,11111282,681,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
35,880,2,1,,26750067,681,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
36,880,2,1,,26750067,681,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
37,880,2,1,,26753787,681,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
38,880,2,1,,26753787,681,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
39,881,2,2,,11111282,681,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
40,881,2,2,,26750067,681,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
41,883,1,3,,11111282,681,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
42,884,1,2,,11111282,681,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
43,884,1,2,,26750067,681,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
44,885,1,2,,11111282,681,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
45,885,1,2,,26750067,681,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
46,886,1,2,,11111282,681,Active,122921310.0,,0.5012,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
47,886,1,2,,11111282,681,Active,122921311.0,,0.5012,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
48,887,1,2,,11111282,681,Inactive,1832253.0,246.0,6.3096,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
49,887,1,2,,26750067,681,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
50,889,1,3,,11111282,681,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
51,889,1,3,,26750067,681,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
52,891,1,2,,11111282,681,Inactive,40805836.0,1565.0,31.6228,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
53,892,1,2,,11111282,681,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
54,892,1,2,,26750067,681,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
55,893,1,2,,11111282,681,Inconclusive,122921310.0,,15.8489,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
56,893,1,2,,11111282,681,Inconclusive,122921311.0,,15.8489,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
57,893,1,2,,26750067,681,Active,122921310.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
58,893,1,2,,26750067,681,Active,122921311.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
59,894,2,1,,26750067,681,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
60,895,1,2,,11111282,681,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
61,899,1,2,,11111282,681,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
62,900,1,3,,11111282,681,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
63,900,1,3,,26750067,681,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
64,901,1,2,,11111282,681,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
65,902,1,2,,11111282,681,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
66,902,1,2,,26750067,681,Inconclusive,120407068.0,7157.0,12.5893,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
67,910,1,2,,26750067,681,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
68,912,1,2,,11111282,681,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
69,914,1,3,,11111282,681,Inconclusive,32879895.0,3091.0,10.0,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
70,915,1,3,,11111282,681,Active,32879895.0,3091.0,10.0,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
71,917,1,3,,11111282,681,Inconclusive,120660324.0,7066.0,3.1623,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
72,918,1,3,,11111282,681,Inconclusive,120660324.0,7066.0,3.1623,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
73,923,1,2,,11111282,681,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
74,923,1,2,,26750067,681,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
75,924,1,2,,11111282,681,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
76,924,1,2,,26750067,681,Active,120407068.0,7157.0,12.5893,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
77,925,1,2,,11111282,681,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
78,926,1,2,,11111282,681,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
79,927,1,3,,11111282,681,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
80,927,1,3,,26750067,681,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
81,928,1,2,,11111282,681,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
82,930,1,2,,26750067,681,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
83,938,1,2,,11111282,681,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
84,940,1,2,,26612791,681,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
85,943,1,2,,11111282,681,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
86,944,1,2,,11111282,681,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
87,945,1,4,,11111282,681,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
88,954,1,2,,11111282,681,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
89,957,1,2,,11111282,681,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
90,958,1,2,,11111282,681,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
91,959,1,4,,11111282,681,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
92,992,1,3,,11111282,681,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
93,995,1,2,,11111282,681,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
94,995,1,2,,26750067,681,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
95,997,1,2,,11111282,681,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
96,998,1,2,,11111282,681,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
97,1030,2,1,,26750067,681,Inactive,30582681.0,216.0,35.4813,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
98,1030,2,1,,26753787,681,Inconclusive,30582681.0,216.0,31.6228,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
99,1204,1,2,,48421926,681,Inactive,,,,,DSSTox (NCTRER) National Center for Toxicological Research Estrogen Receptor Binding Database,Screening,,
100,1379,1,2,,26750067,681,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
101,1422,1,1,,26612791,681,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
102,1452,1,1,,11111282,681,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
103,1452,1,1,,26750067,681,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
104,1454,1,1,,26750067,681,Inconclusive,66932916.0,5594.0,28.1838,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
105,1457,1,1,,26750067,681,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
106,1457,1,1,,26753787,681,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
107,1458,1,1,,26750067,681,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
108,1458,1,1,,26753787,681,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
109,1460,1,3,,26750067,681,Inconclusive,92096784.0,4137.0,1.5849,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
110,1460,1,3,,26753787,681,Inconclusive,92096784.0,4137.0,5.0119,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
111,1463,1,1,,26750067,681,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
112,1463,1,1,,26753787,681,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
113,1467,1,3,,26750067,681,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
114,1468,1,1,,26750067,681,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
115,1468,1,1,,26753787,681,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
116,1469,1,1,,26750067,681,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
117,1469,1,1,,26753787,681,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
118,1471,2,1,,11111282,681,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
119,1471,2,1,,26753787,681,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
120,1476,2,1,,26750067,681,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
121,1478,2,1,,26750067,681,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
122,1479,1,2,,26750067,681,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
123,1479,1,2,,26753787,681,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
124,1487,1,1,,26750067,681,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
125,1487,1,1,,26753787,681,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
126,1490,2,1,,26750067,681,Inconclusive,10954339.0,,1.2589,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
127,1490,2,1,,26753787,681,Active,10954339.0,,79.4328,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
128,1519,1,3,,26750067,681,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
129,1558,1,1,,57288369,681,Inactive,92096784.0,4137.0,,Potency,"Confirmation Concentration-Response Assay for for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
130,1559,1,1,,57288369,681,Inactive,92096784.0,4137.0,,Potency,"Confirmation Concentration-Response Assay for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
131,1688,1,1,,26753787,681,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
132,1694,1,1,,57288369,681,Inactive,92096784.0,4137.0,,Potency,"Confirmation Concentration-Response Assay for Inhibitors of Tau Fibril Formation, Total Fluorescence Counterscreen for Fluorescence Polarization",Confirmatory,,
133,1720,1,1,,57288369,681,Inactive,92096784.0,4137.0,,,Sedimentation Assay for Inhibitors of Tau Fibrillization,Other,,
134,1766,1,1,,26750067,681,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
135,1766,1,1,,26750067,681,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
136,1766,1,1,,26753787,681,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
137,1766,1,1,,26753787,681,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
138,1768,1,1,,26750067,681,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
139,1768,1,1,,26750067,681,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
140,1768,1,1,,26753787,681,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
141,1768,1,1,,26753787,681,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
142,1851,1,2,,11111282,681,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
143,1851,1,2,1.0,11111282,681,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
144,1851,1,2,2.0,11111282,681,Inconclusive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
145,1851,1,2,3.0,11111282,681,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
146,1851,1,2,4.0,11111282,681,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
147,1851,1,2,5.0,11111282,681,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
148,1865,1,1,,26750067,681,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
149,1865,1,1,,26753787,681,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
150,1948,1,1,,26750067,681,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
151,2062,1,2,,85209061,681,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
152,2101,1,1,,26750067,681,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
153,2101,1,1,,26753787,681,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
154,2107,1,1,,26750067,681,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
155,2107,1,1,,26753787,681,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
156,2112,1,1,,26750067,681,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
157,2112,1,1,,26753787,681,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
158,2147,1,1,,26750067,681,Active,221046486.0,,15.8489,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
159,2451,1,2,,26750067,681,Inconclusive,122920737.0,,6.2946,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
160,2472,1,2,,26750067,681,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
161,2517,2,1,,26750067,681,Active,6980812.0,,0.8913,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
162,2517,2,1,,26753787,681,Active,6980812.0,,1.5849,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
163,2528,1,2,,26750067,681,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
164,2528,1,2,,26753787,681,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
165,2546,1,1,,26750067,681,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
166,2546,1,1,,26753787,681,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
167,2549,1,1,,26750067,681,Active,282403581.0,,14.1254,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
168,2549,1,1,,26753787,681,Inconclusive,282403581.0,,1.7783,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
169,2551,1,1,,26750067,681,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
170,2551,1,1,,26753787,681,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
171,2564,1,1,,26753787,681,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Assay,Confirmatory,,
172,2565,1,1,,26753787,681,Inactive,405898.0,,28.1838,Potency,Counterscreen for APE1 Inhibitors: qHTS Assay for Inhibitors of Endonuclease IV,Confirmatory,,
173,2572,1,1,,26753787,681,Inconclusive,6980812.0,,28.1838,Potency,Confirmation qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
174,2573,1,1,,26753787,681,Inconclusive,6980812.0,,1.9953,Potency,qHTS FP-Based Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
175,2660,1,1,,90341661,681,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
176,2666,1,1,,90341661,681,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
177,2667,1,1,,90341661,681,Inconclusive,4826730.0,2475.0,26.1216,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
178,2668,1,1,,90341661,681,Inconclusive,4826730.0,2475.0,23.2809,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
179,2708,1,1,,26750067,681,Inconclusive,282403581.0,,3.16e-05,Potency,Confirmation qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
180,2708,1,1,,26753787,681,Inactive,282403581.0,,,Potency,Confirmation qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
181,2711,1,1,,26750067,681,Active,,,7.9433,Potency,Counterscreen for RECQ1 Inhibitors: ADP Fluorescence Polarization Displacement Assay,Confirmatory,,
182,2711,1,1,,26753787,681,Active,,,89.1251,Potency,Counterscreen for RECQ1 Inhibitors: ADP Fluorescence Polarization Displacement Assay,Confirmatory,,
183,2712,1,1,,26750067,681,Active,,,7.9433,Potency,Counterscreen for BLMA Inhibitors: ADP Fluorescence Polarization Displacement Assay,Confirmatory,,
184,2712,1,1,,26753787,681,Active,,,89.1251,Potency,Counterscreen for BLMA Inhibitors: ADP Fluorescence Polarization Displacement Assay,Confirmatory,,
185,4036,8,5,,103167911,681,Unspecified,112812.0,24473.0,10.0,Ki,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Confirmatory,8230102.0,
186,6428,8,5,,103167911,681,Unspecified,400630.0,6532.0,30.0,IC50,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Confirmatory,14592523.0,
187,18297,6,3,,103167911,681,Active,,,7.8,Km,Michaelis-Menten constant was measured against adenylate cyclase stimulation of cAMP formation in striatal homogenates,Confirmatory,3761308.0,
188,18736,3,3,,103167911,681,Unspecified,,,,,Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membrane without any host,Other,10476872.0,
189,18737,3,3,,103167911,681,Unspecified,,,,,Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membranes incorporated with o-Tolyloxy-acetic acid decyl ester polymer,Other,10476872.0,
190,18738,3,3,,103167911,681,Unspecified,,,,,Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membranes incorporated with o-Tolyloxy-acetic acid ethyl ester polymer,Other,10476872.0,
191,18739,3,3,,103167911,681,Unspecified,,,,,Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membranes incorporated with (2-Butoxy-5-tert-butyl-3-methyl-phenyl)-methanol polymer,Other,10476872.0,
192,18740,3,3,,103167911,681,Unspecified,,,,,"Selectivity of guest-induced changes in membrane potential at pH 5.0 for PVC matrix liquid membranes incorporated with 6,7,9,10,17,18,20,21-Octahydro-5,8,11,16,19,22-hexaoxa-dibenzo[a,j]cyclooctadecene",Other,10476872.0,
193,22293,4,4,,103167911,681,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
194,23236,3,3,,103167911,681,Unspecified,,,,,Partition coefficient (logP),Other,10476872.0,
195,25622,3,3,,103167911,681,Unspecified,,,,,Evaluated for the pKa value.,Other,7097723.0,
196,26304,4,4,,103167911,681,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
197,29359,3,3,,103167911,681,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
198,29811,4,3,,103167911,681,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
199,33127,8,3,,103167911,681,Active,,,0.061,IC50,Concentration that produces 50 % displacement of specific [3H]clonidine binding to Alpha adrenergic receptor in rat brain cortical membrane preparations.,Confirmatory,6317860.0,
200,34288,3,10,,103167911,681,Unspecified,,,,,Compound was evaluated for the elicited effect on adenylate cyclase activity in homogenates of carp retina at 100 uM,Other,7277402.0,
201,34315,7,4,,103167911,681,Active,,,5.0,IC50,Stimulation of Adenylate cyclase from rat striatal membranes,Confirmatory,1971308.0,
202,34316,3,5,,103167911,681,Unspecified,,,,,Percentage maximum stimulation adenylate cyclase was measured versus DA,Other,1971308.0,
203,34435,3,10,,103167911,681,Unspecified,,,,,Ability (50 uM) to stimulate dopamine sensitive adenylate cyclase from rat corpus striatum in the presence of excess ATP,Other,7120288.0,
204,34440,9,3,,103167911,681,Active,,,3.5,EC50,Tested for ability to stimulate dopamine sensitive adenylate cyclase in rat caudate homogenate,Confirmatory,6980283.0,
205,35808,4,1,,103167911,681,Active,,,0.97724,Ki,Compound was tested for its binding affinity against Alpha-2 adrenergic receptor,Confirmatory,,
206,36305,4,1,,103167911,681,Active,,,2.51189,Ki,Compound was tested for its binding affinity against Alpha-1 adrenergic receptor,Confirmatory,,
207,36411,3,9,,103167911,681,Unspecified,,,,,Activity at alpha-1 adrenergic receptor in rabbit aorta rings,Other,,
208,36587,9,1,,103167911,681,Unspecified,,,90.0,IC50,Ability to displace [3H]WB-4101 from rat brain alpha-1 adrenergic receptor,Confirmatory,3950903.0,
209,37459,9,2,,103167911,681,Active,,,14.0,Ki,Binding of [3H]prazosin to alpha-1 adrenergic receptor of rat cerebral cortical membranes,Confirmatory,10780918.0,
210,40408,9,2,,103167911,681,Active,,,10.0,Ki,Binding of [3H]dihydroalprenolol to beta-1 adrenergic receptor of rat cerebral cortical membranes,Confirmatory,10780918.0,
211,40531,4,7,,103167911,681,Unspecified,,,,,Positive inotropic effects by direct or indirect beta-1 adrenergic receptor activation.,Other,3027335.0,
212,41478,9,2,,103167911,681,Unspecified,,,50.0,Ki,Binding of [3H]dihydroalprenolol to beta-2 adrenergic receptor of rat cerebral cortical membranes,Confirmatory,10780918.0,
213,42818,7,2,,103167911,681,Active,,,0.65,Ki,Binding Affinity was tested on low Affinity Site of Bovine Dopamine D1 Receptor. Tested for ability to displace the radioligand [3H]-SCH- 23390 at the binding site.,Confirmatory,10691700.0,
214,42820,7,2,,103167911,681,Active,,,0.011000000000000001,Ki,Binding Affinity was tested on high Affinity Site of Bovine Dopamine D2 Receptor. Tested for ability to displace the radioligand [3H]spiperone was tested,Confirmatory,10691700.0,
215,48354,7,2,,103167911,681,Unspecified,,,,,Inhibition of positive chronotropic effect of the cardioaccelerator was determined,Other,7154005.0,
216,57838,3,3,,103167911,681,Unspecified,,,,,Potency was expressed as the average maximum cumulative dose required to decrease renal vascular resistance by 15%,Other,7411552.0,
217,57843,3,4,,103167911,681,Unspecified,,,,,Cardioselectivity expressed as change in blood pressure for 100% increase in right ventricular contractile force in dogs,Other,7277389.0,
218,57846,3,4,,103167911,681,Unspecified,,,,,Cardioselectivity expressed as change in blood pressure for 50% increase in right ventricular contractile force in dogs,Other,7277389.0,
219,58038,3,4,,103167911,681,Unspecified,,,,,Blockade of dog renal artery dilation by the D-2 antagonist SCH-23390 was measured after intravenous administration of 0.05-0.1 mg/kg,Other,,
220,58655,6,1,,103167911,681,Unspecified,,,,,Ionotropic selectivity expressed as change in heart rate for 100 percent increase in right ventricular contractile force in dogs,Other,7277389.0,
221,58658,6,1,,103167911,681,Unspecified,,,,,Ionotropic selectivity expressed as change in heart rate for 50 percent increase in right ventricular contractile force in dogs,Other,7277389.0,
222,59132,4,3,,103167911,681,Unspecified,,,,,Compound was tested for its renal vasodilator activity in dogs.,Other,6980283.0,
223,59135,3,3,,103167911,681,Unspecified,,,,,Effective Dose (ED15) required to decrease renal vascular resistance by 15% in anesthetized dogs administered intravenously,Other,7411552.0,
224,59139,5,2,,103167911,681,Unspecified,,,,,Renal vasodilator activity was determined in anesthetized dogs,Other,2878077.0,
225,59146,3,4,,103167911,681,Unspecified,,,,,Cardiovascular activity was determined in anesthetized dogs.(Mean arterial blood pressure),Other,2878077.0,
226,59282,3,3,,103167911,681,Unspecified,,,,,cardiovascular activity was determined in anesthetized dogs.(Heart rate ),Other,2878077.0,
227,59294,3,3,,103167911,681,Active,,,,,Compound was tested for the renal vasodilatory activity in anesthetized dog.,Other,3528490.0,
228,59296,3,3,,103167911,681,Unspecified,,,,,Effective dose against Iliac vascular resistance (IVR),Other,2878077.0,
229,60143,3,5,,103167911,681,Unspecified,,,,,Ability to induce dilation of dog renal artery when administered intravenously; Values is potency versus DPDA,Other,,
230,60580,4,1,,103167911,681,Unspecified,,,,,Inotropic potency expressed as 100 percent increase in right ventricular contractile force in dogs,Other,7277389.0,
231,60584,4,1,,103167911,681,Unspecified,,,,,Inotropic potency expressed as 50 percent increase in right ventricular contractile force in dogs,Other,7277389.0,
232,60651,3,3,,103167911,681,Unspecified,,,,,Compound was evaluated for average maximum percent decrease in renal vascular resistance in dogs,Other,7069713.0,
233,60922,3,3,,103167911,681,Unspecified,,,,,Effect of compound on the renal blood flow (RBF) in alpha-blocked anesthetized dogs at a dose of 100 nmol after SCH 23390+propranolol,Other,3528490.0,
234,60923,3,3,,103167911,681,Unspecified,,,,,Effect of compound on the renal blood flow (RBF) in alpha-blocked anesthetized dogs at a dose of 100 nmol after SCH 23390.,Other,3528490.0,
235,60924,3,3,,103167911,681,Unspecified,,,,,Effect of compound on the renal blood flow (RBF) in alpha-blocked anesthetized dogs at a dose of 100 nmol after propranolol,Other,3528490.0,
236,60930,3,3,,103167911,681,Unspecified,,,,,Effect of compound on the renal blood flow (RBF) in alpha-blocked anesthetized dogs at a dose of 30 nmol after SCH 23390+propranolol,Other,3528490.0,
237,60931,3,3,,103167911,681,Unspecified,,,,,Effect of compound on the renal blood flow (RBF) in alpha-blocked anesthetized dogs at a dose of 30 nmol after SCH 23390.,Other,3528490.0,
238,60932,3,3,,103167911,681,Unspecified,,,,,Effect of compound on the renal blood flow (RBF) in alpha-blocked anesthetized dogs at a dose of 30 nmol after propranolol,Other,3528490.0,
239,60945,3,3,,103167911,681,Active,,,,,Renal blood flow was measured in dogs; Highly significant activity,Other,7069713.0,
240,60958,3,4,,103167911,681,Active,,,,,Renal vascular resistance was calculated as the ratio of the mean arterial blood pressure / mean renal blood flow; Highly significant activity,Other,7069713.0,
241,60961,3,3,,103167911,681,Unspecified,,,,,Compound was evaluated for determining renal vascular resistance(iv) in dogs,Other,7069713.0,
242,60994,3,4,,103167911,681,Unspecified,,,,,Growth inhibition of Don-6 cell lines at 1.0 mM concentration,Other,6788955.0,
243,61002,3,9,,103167911,681,Unspecified,128613.0,24898.0,,,The maximum dopamine release induced by perfusion with the test compound with basal striatal DA (%of basal x10E-3),Other,2374149.0,
244,61010,4,6,,103167911,681,Active,,,5.0,EC50,Effective concentration was determined for the adenylate cyclase activity in rat striatal tissue as a measure of Dopamine receptor D1 functional activity,Confirmatory,8568818.0,
245,61011,4,1,,103167911,681,Unspecified,,,,,Tested for its ability to stimulate rat caudate adenylate cyclase (Dopamine receptor D1) at 10 uM,Other,4068005.0,
246,61013,8,1,,103167911,681,Active,,,3.5,ED50,The ability of a compound to stimulate dopamine-sensitive rat caudate adenylate cyclase or to antagonise the stimulant of dopamine was used as measure of D1 efficacy,Confirmatory,2875183.0,
247,61036,9,2,,103167911,681,Active,,,3.0,IC50,Compound was evaluated for the inhibition of [3H]-SCH- 23390 binding to Dopamine receptor D1 of rat striatal membranes,Confirmatory,1975274.0,
248,61145,3,9,,103167911,681,Unspecified,118205.0,281126.0,,,"Low percent binding affinity for different states of the Dopamine receptor D2 in bovine anterior pituitary membranes, using radioligand [3H]spiroperidol",Other,2565402.0,
249,61147,9,3,,103167911,681,Active,,,0.2,IC50,In vitro binding affinity towards Dopamine D1 receptor using [3H]-SCH- 23390 as radioligand,Confirmatory,,
250,61192,9,1,,103167911,681,Active,,,3.7,IC50,Inhibitory activity against [3H]-SCH- 23390 in Rat Striatal membrane,Confirmatory,1360027.0,
251,61209,6,4,,103167911,681,Inconclusive,,,,,Tested for its ability to inhibit rat caudate adenylate cyclase (Dopamine receptor D1) at 10 uM; e=Value not determined,Other,4068005.0,
252,61211,3,6,,103167911,681,Unspecified,,,,,The percentage stimulation of adenylate cyclase activity of compound was measured on dopamine receptor D1 of Rat Striatum at 0.01 uM,Other,1360027.0,
253,61212,3,6,,103167911,681,Unspecified,,,,,The percentage stimulation of adenylate cyclase activity of compound was measured on dopamine receptor D1 of Rat Striatum at 0.1 uM,Other,1360027.0,
254,61213,4,4,,103167911,681,Unspecified,,,,,The percentage stimulation of adenylate cyclase activity of compound was measured on dopamine receptor D1 of Rat Striatum at 10 uM,Other,1360027.0,
255,61221,7,1,,103167911,681,Active,,,0.008,EC50,In vitro effective concentration tested on HEK293 cells co-transfected with ferret Dopamine receptor D2 using FLIPR assay,Confirmatory,15239663.0,
256,61225,7,1,,103167911,681,Active,,,0.0011,EC50,In vitro effective concentration tested on HEK293 cells co-transfected with rat Dopamine receptor D2 using FLIPR assay,Confirmatory,15239663.0,
257,61244,3,6,,103167911,681,Unspecified,,,,,In vitro efficacy tested on ferret Dopamine receptor D2 were co-expressed with GRqo5 in HEK293 cells using FLIPR assay (Efficacy relative to 10 uM dopamine),Other,15239663.0,
258,61246,3,6,,103167911,681,Unspecified,,,,,In vitro efficacy tested on rat Dopamine receptor D2 were co-expressed with GRqo5 in HEK293 cells using FLIPR assay (Efficacy relative to 10 uM dopamine),Other,15239663.0,
259,61305,9,3,,103167911,681,Active,,,8.0,IC50,In vitro binding affinity towards Dopamine D2 receptor using [3H]spiperone as radioligand,Confirmatory,,
260,61342,3,9,,103167911,681,Unspecified,118229.0,24316.0,,,Percent stimulation of adenylate cyclase activity at dopamine receptor D1 of Rat Striatum at 1 uM,Other,1360027.0,
261,61344,7,1,,103167911,681,Active,,,,,Inhibitory activity against Dopamine receptor D1 by displacement of [3H]fenoldopam from homogenated rat striatum,Other,2886663.0,
262,61345,3,6,,103167911,681,Active,,,,,"Affinity towards Dopamine receptor D1 was evaluated in rat striatal membrane using [3H]SCH-23,390 as radioligand",Other,8568818.0,
263,61354,7,1,,103167911,681,Active,,,,,Affinity for Dopamine receptor D1 binding sites was evaluated in a test involving displacement of [3H]- fenoldopam in rat striatum,Other,2875183.0,
264,61356,3,6,,103167911,681,Active,,,,,Binding affinity against the Dopamine D1 receptor by the displacement of [3H]fenoldopam from homogenized rat striatum,Other,2955118.0,
265,61509,7,2,,103167911,681,Unspecified,,,1.0,Ki,Binding affinity at Dopamine receptor D1 in rat neostriatum by [3H]-SCH- 23390 displacement.,Confirmatory,8863801.0,
266,61510,8,5,,103167911,681,Active,118229.0,24316.0,0.15,Ki,Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranes,Confirmatory,3761310.0,
267,61518,9,1,,103167911,681,Active,,,4.4,Ki,In vitro affinity against Dopamine receptor D1 using [3H]SCH-23390 radioligand in rat striatal homogenate.,Confirmatory,3761308.0,
268,61554,9,2,,103167911,681,Active,,,2.2,IC50,Compound was evaluated for the inhibition of [3H]spiperone binding to Dopamine receptor D2 of rat striatal membranes,Confirmatory,1975274.0,
269,61560,9,2,,103167911,681,Active,,,1.2,IC50,Compound was for its ability to displace [3H]haloperidol binding to rat striatal Dopamine receptor D2,Confirmatory,3950903.0,
270,61612,8,5,,103167911,681,Active,118206.0,1813.0,0.0018899999999999998,Ki,Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells,Confirmatory,10465538.0,
271,61613,8,5,,103167911,681,Active,118206.0,1813.0,0.759,Ki,Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells,Confirmatory,10465538.0,
272,61619,4,5,,103167911,681,Unspecified,,,,,"Inhibition of [35S]GTP-gamma-S, binding to cell membranes expressing dopamine D2A receptors at 100 uM",Other,10465538.0,
273,61664,3,7,,103167911,681,Unspecified,,,,,Selectivity index of D1 receptor to that of D2 receptor was determined,Other,1360027.0,
274,61669,4,1,,103167911,681,Active,,,0.41686999999999996,Ki,Binding Affinity was determined against Dopamine receptor D1 in rat striatal membranes using [3H]- SCH 23390 radioligand.,Confirmatory,10691686.0,
275,61674,4,1,,103167911,681,Active,118229.0,24316.0,0.30903,Ki,Binding affinity against Dopamine receptor D1 in rat striatal membranes using [3H]SCH-23390,Confirmatory,,
276,61752,3,3,,103167911,681,Unspecified,,,,,Maximum percent decrease in renal vascular resistance.,Other,2878077.0,
277,61822,7,2,,103167911,681,Active,,,0.192,Ki,Binding affinity to displace [3H]- SCH 23390 against Dopamine receptor D1,Confirmatory,1973733.0,
278,61852,8,5,,103167911,681,Active,110832828.0,281125.0,4.3,Ki,Binding affinity against Dopamine receptor D1 like from bovine retina membranes measured using [3H]SCH-23390 radioligand,Confirmatory,9836610.0,
279,61855,8,5,,103167911,681,Active,110832828.0,281125.0,4.3,Ki,Binding affinity for dopamine D1-like receptor labelled with [3H]SCH-23390 in retina,Confirmatory,11206464.0,
280,61860,3,7,,103167911,681,Unspecified,,,,,Dopamine receptor D1 like evaluated for mesenteric blood flow increase in anesthetized rabbit,Other,,
281,61865,8,5,,103167911,681,Active,118228.0,1812.0,2.5,Kd,Equilibrium dissociation constant against recombinant Dopamine receptor D1A expressed in COS7 cells,Confirmatory,8632409.0,
282,61867,3,9,,103167911,681,Unspecified,118228.0,1812.0,,,log(1/Kd) value against recombinant Dopamine receptor D1A expressed in COS7 cell,Other,8632409.0,
283,61996,3,9,,103167911,681,Active,118229.0,24316.0,,,Low-affinity agonist dissociation constant against striatal Dopamine receptor D1A,Other,8632409.0,
284,62028,5,3,,103167911,681,Inconclusive,,,,,"The compound was tested for its ability to inhibit specific [3H]spiroperidol binding to bovine anterior pituitary homogenate, at 10 uM; e=Value not determined",Other,4068005.0,
285,62165,8,5,,103167911,681,Active,118205.0,281126.0,4.7,IC50,Displacement of [3H]spiroperidol from homogenized bovine pituitary Dopamine receptor D2,Confirmatory,2955118.0,
286,62184,7,1,,103167911,681,Active,,,,,Inhibitory activity against Dopamine receptor D2 by displacement of [3H]spiroperidol from bovine pituitary,Other,2886663.0,
287,62187,6,4,,103167911,681,Active,,,,,"The compound was tested for its ability to inhibit specific [3H]spiroperidol binding to bovine anterior pituitary homogenate, at 10 uM",Other,4068005.0,
288,62188,7,1,,103167911,681,Active,,,,,Affinity for Dopamine receptor D2 was evaluated from the ability to displace [3H]spiroperidol from homogenized bovine pituitary,Other,2875183.0,
289,62319,7,2,,103167911,681,Active,,,0.0018,Ki,Binding Affinity on high Affinity Site of Bovine dopamine receptor D2. Tested for ability to displace the radioligand [3H]pramipexole was tested,Confirmatory,10691700.0,
290,62321,7,2,,103167911,681,Active,,,1.6,Ki,Binding Affinity was determined for its ability to displace the radioligand [3H]spiperone from low Affinity Site of Bovine dopamine receptor D2.,Confirmatory,10691700.0,
291,62326,7,2,,103167911,681,Active,,,0.051,Ki,Binding Affinity was tested on relative proportion of high Affinity Site of Bovine dopamine receptor D2. Tested for ability to displace the radioligand [3H]spiperone at the binding site.,Confirmatory,10691700.0,
292,62333,7,2,,103167911,681,Active,,,2.35,Ki,Compound was tested for inhibition of [3H]spiroperidol binding against Dopamine receptor D2,Confirmatory,3761310.0,
293,62339,7,1,,103167911,681,Active,,,0.034,Ki,"High binding affinity for dopamine D-2 receptor from bovine anterior pituitary membrane, using radioligand [3H]spiroperidol",Confirmatory,2565402.0,
294,62445,9,2,,103167911,681,Active,,,0.064,IC50,Inhibition of [3H]dopamine binding to Dopamine receptor in calf caudate nuclei.,Confirmatory,6106063.0,
295,62446,9,2,,103167911,681,Active,,,1.7,IC50,Inhibition of [3H]haloperidol binding to Dopamine receptor in calf caudate nuclei.,Confirmatory,6106063.0,
296,62448,8,1,,103167911,681,Active,,,0.51,IC50,Inhibitory binding activity against dopamine receptor using [3H]ADTN as the radioligand in striatal tissue of calf brain.,Confirmatory,7154005.0,
297,62450,8,1,,103167911,681,Unspecified,,,150.0,IC50,Inhibitory binding activity against dopamine receptor using [3H]spiperone as the radioligand in striatal tissue of calf brain.,Confirmatory,7154005.0,
298,62451,7,1,,103167911,681,Active,,,0.0037,IC50,Tested for binding to dopamine receptor using [3H]- ADTN as radioligand in calf caudate nucleus homogenates.,Confirmatory,7120288.0,
299,62452,7,1,,103167911,681,Active,,,0.0045,IC50,Tested for binding to dopamine receptor using [3H]apomorphine as radioligand in calf caudate nucleus homogenates.,Confirmatory,7120288.0,
300,62453,7,1,,103167911,681,Unspecified,,,10.0,IC50,Tested for binding to dopamine receptor using [3H]spiroperidol as radioligand in calf caudate nucleus homogenates.,Confirmatory,7120288.0,
301,62478,8,5,,103167911,681,Active,118205.0,281126.0,3.38,Ki,"Low binding affinity for dopamine D-2 receptor from bovine anterior pituitary membrane, using radioligand [3H]spiroperidol",Confirmatory,2565402.0,
302,62571,3,8,,103167911,681,Unspecified,,,,,Compound was evaluated for the competitive binding with [3H]NCA binding to Canine striatal membranes.,Other,6737423.0,
303,62573,6,2,,103167911,681,Active,,,0.015,IC50,"The IC50 value was reported as apparent, since [3H]NCA was purported to be irreversible. Result indicates the mean of two separate experiments, each performed in triplicate.",Confirmatory,6737423.0,
304,62622,3,9,,103167911,681,Unspecified,118205.0,281126.0,,,"Low percent binding affinity for different states of the Dopamine D-2 receptor in bovine anterior pituitary membranes, using radioligand [3H]spiroperidol",Other,2565402.0,
305,62635,5,4,,103167911,681,Active,,,8e-09,IC50,Agonist required to inhibit Dopamine receptor D2 photoinactivation by 50% with Iodazidoclebopride using [3H]-Spiperone,Confirmatory,3156993.0,
306,62748,7,1,,103167911,681,Active,,,0.17,EC50,Adenylate cyclase assay carried out in LTK cells transfected with human Dopamine receptor D2,Confirmatory,7658429.0,
307,62753,7,1,,103167911,681,Active,,,0.018000000000000002,EC50,In vitro effective concentration tested on HEK293 cells co-transfected with human Dopamine receptor D2 using FLIPR assay,Confirmatory,15239663.0,
308,62762,3,6,,103167911,681,Unspecified,,,,,In vitro efficacy tested on human Dopamine receptor D2 were co-expressed with GRqo5 in HEK293 cells using FLIPR assay (Efficacy relative to 10 uM dopamine),Other,15239663.0,
309,62764,4,7,,103167911,681,Unspecified,,,,,Intrinsic activity relative to dopamine for human Dopamine receptor D2,Other,7658429.0,
310,62878,9,2,,103167911,681,Active,,,5.34,IC50,Tested for Dopamine receptor activity by the inhibition against spiroperidol binding to rat caudate tissue.,Confirmatory,6980283.0,
311,62918,7,1,,103167911,681,Active,,,0.26,Ki,Binding affinity against cloned human Dopamine receptor D2 using [3H]spiperone as radioligand transfected in HEK cells,Confirmatory,7658429.0,
312,63033,8,5,,103167911,681,Active,266667.0,6531.0,0.46,IC50,Inhibition of [3H]dopamine uptake in HEK cells expressing human DAT,Confirmatory,14592523.0,
313,63040,9,2,,103167911,681,Active,,,18.2,Ki,Affinity towards Dopamine receptor D1,Confirmatory,9784114.0,
314,63075,7,3,,103167911,681,Active,,,0.0018899999999999998,Ki,Displacement of [3H]quinpirole from Dopamine receptor D2,Confirmatory,8893836.0,
315,63076,8,5,,103167911,681,Active,118206.0,1813.0,0.5720000000000001,Ki,Inhibition of [3H]raclopride binding to Dopamine receptor D2,Confirmatory,8893836.0,
316,63120,3,3,,103167911,681,Unspecified,,,,,Evaluated for the percentage vasodilation in the renal artery produced by 47 nmol administered intra-arterially.,Other,7097723.0,
317,63174,7,2,,103167911,681,Active,,,1.6,Ki,Binding Affinity was determined for its ability to displace the radioligand [3H]-SCH- 23390 from Bovine dopamine receptor D1,Confirmatory,10691700.0,
318,63176,7,2,,103167911,681,Active,,,0.006999999999999999,Ki,Binding Affinity was tested on High Affinity Site of Bovine Dopamine receptor D1. Tested for ability to displace the radioligand [3H]-SCH- 23390,Confirmatory,10691700.0,
319,63178,7,2,,103167911,681,Active,,,0.036000000000000004,Ki,Binding Affinity was tested on relative proportion of High Affinity Site of Bovine dopamine receptor D1. Tested for ability to displace the radioligand [3H]-SCH- 23390 at the binding site.,Confirmatory,10691700.0,
320,63203,6,4,,103167911,681,Unspecified,,,12000.0,Ki,Binding Affinity was determined for its ability to displace the radioligand [3H]spiperone from Bovine dopamine receptor D1.,Confirmatory,10691700.0,
321,63211,7,1,,103167911,681,Active,,,0.1,EC50,Adenylate cyclase assay carried out in LTK cells transfected with human Dopamine receptor D1,Confirmatory,7658429.0,
322,63227,9,2,,103167911,681,Active,,,7.94,Ki,Affinity towards Dopamine receptor D2,Confirmatory,9784114.0,
323,63237,3,9,,103167911,681,Unspecified,118206.0,1813.0,,,Inhibition of [35 S] GTP gamma S binding to cell membranes expressing Dopamine receptor D2,Other,8893836.0,
324,63239,3,9,,103167911,681,Unspecified,118206.0,1813.0,,,Hill coefficients for [3H]-raclopride binding to dopamine D2 receptor high-and low-affinity agonist states,Other,8893836.0,
325,63338,3,7,,103167911,681,Unspecified,,,,,Intrinsic activity relative to dopamine for human Dopamine receptor D1,Other,7658429.0,
326,63344,7,1,,103167911,681,Active,,,0.13,Ki,Binding affinity against cloned human Dopamine receptor D1 using [125I]-SCH 23982 as radioligand transfected in HEK cells,Confirmatory,7658429.0,
327,63370,8,5,,103167911,681,Active,118229.0,24316.0,0.8,IC50,Displacement of [3H]- #NAME? from binding Dopamine receptor D1 in rat striatum,Confirmatory,1971308.0,
328,63378,4,7,,103167911,681,Active,,,3.5,EC50,Dopamine receptor D1 agonist efficacy was measured with stimulation of dopamine-sensitive rat adenylate cyclase in caudate membranes,Confirmatory,2955118.0,
329,63703,7,1,,103167911,681,Active,,,0.0027,EC50,In vitro effective concentration tested on HEK293 cells co-transfected with ferret Dopamine receptor D4 using FLIPR assay,Confirmatory,15239663.0,
330,63794,4,1,,103167911,681,Active,,,0.72444,Ki,Binding Affinity was determined against Dopamine receptor D2 in rat striatal membranes using [3H]- spiperone radioligand.,Confirmatory,10691686.0,
331,63808,4,1,,103167911,681,Active,47117674.0,24318.0,0.10471,Ki,Binding affinity against Dopamine receptor D2 in rat striatal membranes using [3H]spiperone,Confirmatory,,
332,63828,7,1,,103167911,681,Active,,,0.0024,EC50,In vitro effective concentration tested on HEK293 cells co-transfected with rat Dopamine receptor D4 using FLIPR assay,Confirmatory,15239663.0,
333,63830,3,6,,103167911,681,Unspecified,,,,,In vitro efficacy tested on ferret Dopamine receptor D4 were co-expressed with GRqo5 in HEK293 cells using FLIPR assay (Efficacy relative to 10 uM dopamine),Other,15239663.0,
334,63831,3,6,,103167911,681,Unspecified,,,,,In vitro efficacy tested on rat Dopamine receptor D4 were co-expressed with GRqo5 in HEK293 cells using FLIPR assay (Efficacy relative to 10 uM dopamine),Other,15239663.0,
335,63853,7,3,,103167911,681,Active,,,0.015,Ki,Binding affinity for dopamine D4-like receptor labelled with [3H]YM-09151-2 in retina,Confirmatory,11206464.0,
336,64027,7,2,,103167911,681,Active,,,0.09699999999999999,Ki,Binding Affinity was determined in the presence of 100 micro M Gpp(NH)p for decoupling of the ternary complex of Compound to Dopamine receptor D4.4,Confirmatory,10691700.0,
337,64028,11,2,,103167911,681,Active,1345939.0,1815.0,0.0012,Ki,Binding Affinity was tested on the high affinity site of Dopamine receptor D4.4,Confirmatory,10691700.0,
338,64029,7,2,,103167911,681,Active,,,0.062,Ki,Binding Affinity was tested on low Affinity Site of Dopamine receptor D4.4,Confirmatory,10691700.0,
339,64030,7,2,,103167911,681,Active,,,0.057,Ki,Binding Affinity was tested on relative proportion of High Affinity Site of Dopamine receptor D4.4,Confirmatory,10691700.0,
340,64170,8,5,,103167911,681,Active,118205.0,281126.0,0.617,Ki,Tested for binding affinity against Dopamine receptor D2 like from bovine striatum membranes by using [3H]YM-09151-2 radioligand,Confirmatory,9836610.0,
341,64172,8,5,,103167911,681,Active,118205.0,281126.0,0.0149,Ki,"Inhibition of [3H]YM-09151-2 binding to bovine retina membrane Dopamine receptor D2, high affinity site",Confirmatory,9836610.0,
342,64173,8,5,,103167911,681,Active,118205.0,281126.0,1.52,Ki,"Inhibition of [3H]YM-09151-2 binding to bovine retina membrane Dopamine receptor D2, low affinity site",Confirmatory,9836610.0,
343,64279,9,1,,103167911,681,Active,,,5.34,IC50,Concentration that produces 50 % displacement of specific [3H]spiroperidol binding to rat caudate membrane preparations.,Confirmatory,6317860.0,
344,64282,8,5,,103167911,681,Active,47117674.0,24318.0,1.5,IC50,Displacement of [3H]- -spiperone from Dopamine receptor D2 in rat striatum,Confirmatory,1971308.0,
345,64298,3,8,,103167911,681,Unspecified,,,,,Activity at Dopamine receptor D2 in rabbit ear artery,Other,,
346,64302,4,5,,103167911,681,Active,,,0.13,Ki,Binding affinity for dopamine D2-D3 like receptor labelled with [3H]YM-09151-2 in striatum,Confirmatory,11206464.0,
347,64314,7,1,,103167911,681,Active,,,17.0,Kd,Equilibrium dissociation constant against recombinant Dopamine receptor D2A expressed in COS7 cells,Confirmatory,8632409.0,
348,64319,7,2,,103167911,681,Active,,,0.042,Ki,Binding Affinity was tested on relative proportion of High Affinity Site of Dopamine receptor D2L,Confirmatory,10691700.0,
349,64328,11,1,,103167911,681,Active,,,15.0,Ki,Binding Affinity was determined in the presence of 100 micro M Gpp(NH)p for decoupling of the ternary complex of Compound to Dopamine receptor D2L,Confirmatory,10691700.0,
350,64329,11,2,,103167911,681,Active,118206.0,1813.0,0.02,Ki,Binding affinity on High Affinity Site of Dopamine receptor D2L,Confirmatory,10691700.0,
351,64330,11,1,,103167911,681,Active,,,1.9,Ki,Binding Affinity was tested on low Affinity Site of Dopamine receptor D2L,Confirmatory,10691700.0,
352,64438,7,1,,103167911,681,Active,,,1.86,IC50,Inhibition of 0.1 nM of [125I]- (S)-N-(1-Ethyl-pyrrolidin-2-ylmethyl)-5-iodo-2-methoxy-benzamide binding in striatal homogenates of rat brain,Confirmatory,3172140.0,
353,64439,7,1,,103167911,681,Active,,,1.7,IC50,Inhibition of [3H](S)-sulpiride binding in striatal homogenates of rat brain,Confirmatory,3172140.0,
354,64460,9,1,,103167911,681,Active,,,3.5,IC50,Inhibitory activity against [3H]spiperone in Rat Striatal membrane,Confirmatory,1360027.0,
355,64503,8,5,,103167911,681,Active,266667.0,6531.0,6.4,Ki,Displacement of [125I]RT155 binding in HEK cells expressing human DAT,Confirmatory,14592523.0,
356,64600,7,1,,103167911,681,Active,,,3.045,IC50,Neuroleptic activity in terms of [3H]spiroperidol binding in rat striatal membrane to Dopamine receptor D2,Confirmatory,1671414.0,
357,64656,11,1,,103167911,681,Active,,,1.1,Ki,Binding Affinity of Compound of Dopamine receptor D2S,Confirmatory,10691700.0,
358,64657,11,1,,103167911,681,Active,,,15.0,Ki,Binding Affinity was determined in the presence of 100 micro M Gpp(NH)p for decoupling of the ternary complex of Compound to Dopamine receptor D2S,Confirmatory,10691700.0,
359,64658,11,2,,103167911,681,Active,118206.0,1813.0,0.017,Ki,Binding Affinity on High Affinity Site of Dopamine receptor D2S,Confirmatory,10691700.0,
360,64659,7,2,,103167911,681,Active,,,0.034,Ki,Binding Affinity was tested on relative proportion of High Affinity Site of Dopamine receptor D2S,Confirmatory,10691700.0,
361,64774,3,7,,103167911,681,Unspecified,,,,,The percentage inhibition of adenylate cyclase activity of compound was measured on dopamine receptor D2 of Rat Striatum at 0.01 micro M,Other,1360027.0,
362,64775,3,7,,103167911,681,Unspecified,,,,,The percentage inhibition of adenylate cyclase activity of compound was measured on dopamine receptor D2 of Rat Striatum at 0.1 micro M,Other,1360027.0,
363,64776,3,7,,103167911,681,Unspecified,,,,,The percentage inhibition of adenylate cyclase activity of compound was measured on dopamine receptor D2 of Rat Striatum at 10 micro M,Other,1360027.0,
364,64777,3,7,,103167911,681,Unspecified,,,,,The percentage inhibition of adenylate cyclase activity of compound was measured on dopamine receptor D2 of Rat Striatum at 1 micro M,Other,1360027.0,
365,64779,3,6,,103167911,681,Active,,,,,Affinity towards Dopamine receptor D2 was evaluated in rat striatal membrane using [3H]spiperone as radioligand,Other,8568818.0,
366,64788,3,9,,103167911,681,Active,47117674.0,24318.0,,,Low-affinity agonist dissociation constant against striatal Dopamine receptor D2,Other,8632409.0,
367,64790,9,2,,103167911,681,Unspecified,,,267.0,Kd,In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes.,Confirmatory,10956209.0,
368,64917,9,2,,103167911,681,Active,,,37.0,Kd,In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes.,Confirmatory,10956209.0,
369,64919,9,2,,103167911,681,Active,,,49.0,Kd,In vitro affinity at mutant D2 receptor (S197A) in C6 (glioma) cell membranes.,Confirmatory,10956209.0,
370,64925,9,1,,103167911,681,Active,,,6.2,Kd,In vitro affinity at wild type Dopamine receptor D2 on C6 (glioma) cell membranes.,Confirmatory,10956209.0,
371,64970,7,2,,103167911,681,Active,,,0.29,Ki,Binding Affinity was determined in the presence of 100 micro M Gpp(NH)p for decoupling of the ternary complex of Compound to Dopamine receptor D3,Confirmatory,10691700.0,
372,64971,8,5,,103167911,681,Active,1169206.0,1814.0,0.05,Ki,Binding Affinity was tested on the high affinity site of Dopamine receptor D3,Confirmatory,10691700.0,
373,64972,7,2,,103167911,681,Active,,,1.6,Ki,Binding Affinity was tested on low Affinity Site of Dopamine receptor D3,Confirmatory,10691700.0,
374,64973,7,2,,103167911,681,Active,,,0.052000000000000005,Ki,Binding Affinity was tested on relative proportion of High Affinity Site of Dopamine receptor D3,Confirmatory,10691700.0,
375,65092,7,1,,103167911,681,Unspecified,,,1.0,Ki,Binding affinity at Dopamine receptor D2 in rat striatal homogenate by [3H]-spiperone displacement.,Confirmatory,8863801.0,
376,65128,8,5,,103167911,681,Active,1169206.0,1814.0,0.0132,Ki,Displacement of [3H]raclopride from Dopamine receptor D3,Confirmatory,8893836.0,
377,65301,3,9,,103167911,681,Unspecified,1169206.0,1814.0,,,Inhibition of [35 S] GTP gamma S binding to cell membranes expressing Dopamine receptor D3 with dopamine,Other,8893836.0,
378,65302,3,9,,103167911,681,Unspecified,1169206.0,1814.0,,,Hill coefficient for [3H]raclopride binding where high-and low-affinity agonist states for Dopamine receptor D3,Other,8893836.0,
379,65494,8,2,,103167911,681,Unspecified,,,5.0,Ki,Inhibitory constant towards reuptake of [125I]-12 from dopamine transporter in rat striatal membranes,Confirmatory,8182712.0,
380,65613,8,1,,103167911,681,Active,,,0.011000000000000001,Ki,Binding affinity which represents concentration giving half-maximal inhibition of [3H]7-OH-DPAT binding to Dopamine receptor D3 in rat tissue homogenate,Confirmatory,9748351.0,
381,65625,7,1,,103167911,681,Active,,,0.0493,Ki,Tested for binding affinity against dopamine receptor D3 expressed in Sf9 cells.,Confirmatory,8098771.0,
382,65716,9,1,,103167911,681,Active,,,0.015,Ki,"In vitro affinity against Dopamine receptor D2 using [3H]DP-5,6-ADTN radioligand in rat striatal homogenate.",Confirmatory,3761308.0,
383,65751,8,5,,103167911,681,Active,47117674.0,24318.0,0.843,Ki,Competitive binding assay against Dopamine receptor D2 in rat striatal membranes and [125I]-IBF radioligand,Confirmatory,2136916.0,
384,65881,7,1,,103167911,681,Active,,,0.29600000000000004,Ki,Inhibitory constant against binding of [125I]- IBZM to rat striatal membrane,Confirmatory,2966245.0,
385,65928,7,1,,103167911,681,Active,,,0.0022,EC50,In vitro effective concentration tested on HEK293 cells co-transfected with human Dopamine receptor D4 using FLIPR assay,Confirmatory,15239663.0,
386,65932,3,7,,103167911,681,Unspecified,,,,,In vitro efficacy tested on human Dopamine receptor D4 were co-expressed with GRqo5 in HEK293 cells using FLIPR assay (Efficacy relative to 10 uM dopamine),Other,15239663.0,
387,72275,6,5,,103167911,681,Unspecified,,,100.0,IC50,Inhibition of peptide EPQ (pY) EEIPI binding to Fyn protein kinase SH2 domain at 100 uM (no inhibition),Confirmatory,,
388,73725,6,2,,103167911,681,Active,,,1.7,EC50,Effective concentration for increasing potency force in guinea pig isolated left atria,Confirmatory,7277389.0,
389,73727,6,2,,103167911,681,Active,,,1.5,EC50,Effective concentration for increasing potency rate in guinea pig isolated right atria,Confirmatory,7277389.0,
390,76919,3,4,,103167911,681,Unspecified,,,,,Compound was tested for or relative intrinsic activity in guinea pig isolated atrium left atria,Other,7277389.0,
391,76920,3,4,,103167911,681,Unspecified,,,,,Compound was tested for relative intrinsic activity in guinea pig isolated atrium right atria,Other,7277389.0,
392,107885,12,2,,103167911,681,Active,1346544.0,4543.0,7.1,Ki,Displacement of 2-[125I]iodomelatonin from human Melatonin receptor type 1A expressed in CHO cells,Confirmatory,,
393,108050,8,5,,103167911,681,Active,1346548.0,4544.0,9.1,Ki,Inhibition of 2-[125I]iodomelatonin binding to human Melatonin receptor type 1B expressed in CHO cells,Confirmatory,,
394,132337,6,2,,103167911,681,Active,,,10.0,IC50,Compound concentration that causes inhibition of [3H]-acetyl choline release by 50% was determined using reserpine-alpha MPT treated mice striatal slices,Confirmatory,6143827.0,
395,135327,6,1,,103167911,681,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
396,145365,8,5,,103167911,681,Unspecified,128616.0,6530.0,28.0,Ki,Displacement of [125I]RT155 binding in HEK cells expressing human NET,Confirmatory,14592523.0,
397,145556,8,5,,103167911,681,Active,128616.0,6530.0,0.00663,IC50,Inhibition of [3H]norepinephrine uptake in HEK cells expressing human NET,Confirmatory,14592523.0,
398,145934,7,2,,103167911,681,Active,,,3.045,IC50,Ability to inhibit the specific binding of [3H]- dihydromorphine to opiate receptors in rat brain membrane preparation by 50%,Confirmatory,2888899.0,
399,167274,4,3,,103167911,681,Active,,,0.076,EC50,Ability to relax the electrically stimulated rabbit ear artery was determined,Confirmatory,2955118.0,
400,167290,4,3,,103167911,681,Active,,,0.038,EC50,Inhibition of the constrictor response to electrical stimulation in rabbit ear artery.,Confirmatory,2871192.0,
401,167471,8,1,,103167911,681,Active,,,37.0,ED50,The D2 efficacy was evaluated in isolated perfused rabbit ear artery test,Confirmatory,2875183.0,
402,167710,4,3,,103167911,681,Active,,,0.073,EC50,Ability to stimulate peripheral prejunctional dopaminergic receptors by 50% inhibition of vasoconstrictor response to field stimulation in isolated perfused rabbit ear artery,Confirmatory,3712384.0,
403,167713,5,1,,103167911,681,Active,,,0.037000000000000005,ED50,The compound was tested for DA agonistic activity in the isolated perfused rabbit ear artery.,Confirmatory,4068005.0,
404,170168,4,3,,103167911,681,Unspecified,,,,,Effect on DA-sensitive adenylate cyclase activity in rat striatal homogenates,Other,7069700.0,
405,170331,4,3,,103167911,681,Unspecified,,,,,Effect on stimulatory activity of exogenous DA toward DA-sensitive adenylate cyclase activity in rat striatal homogenates,Other,7069700.0,
406,171717,3,3,,103167911,681,Unspecified,,,,,% Change in renal vascular resistance in rats when administered at dose 0.3 ug/kg intravenously,Other,6106062.0,
407,171719,3,3,,103167911,681,Unspecified,,,,,% Change in renal vascular resistance in rats when administered at dose 3 ug/kg intravenously,Other,6106062.0,
408,173703,3,3,,103167911,681,Unspecified,,,,,Percent decrease in serum prolactin concentration in male rats,Other,6834384.0,
409,173829,3,3,,103167911,681,Unspecified,,,,,Percent control of stimulation of cAMP production in rat striatal homogenate at 50 micro M concentration,Other,6682147.0,
410,174069,2,5,,103167911,681,Unspecified,,,,,Compound was tested for mean blood pressure effect in conscious spontaneously hypertensive rats after peroral administration of 30 mg/kg,Other,,
411,174683,2,5,,103167911,681,Unspecified,,,,,Compound was tested for urine flow in conscious spontaneously hypertensive rats after peroral administration of 30 mg/kg,Other,,
412,175327,6,2,,103167911,681,Active,,,3.5,EC50,Adenylase cyclase activity in rat striatal membranes,Confirmatory,7069713.0,
413,175474,7,2,,103167911,681,Active,,,3.5,EC50,Central dopaminergic activity was determined by testing compound for dopamine agonist activity mediated by adenylase cyclase in rat,Confirmatory,7411552.0,
414,175841,6,2,,103167911,681,Active,,,3.5,EC50,In vitro dose stimulating D-1 adenylate cyclase in rat caudate nuclei,Confirmatory,2878077.0,
415,186062,3,3,,103167911,681,Unspecified,,,,,"Compound was tested for maximum response, the percent of cyclic AMP induced by 5 x 10 E-5 M dopamine",Other,6980283.0,
416,187178,4,3,,103167911,681,Unspecified,,,3.0,Ki,Inhibition constant of compound on R-(+)-125[I]-8 radioligand binding to rat striatal membranes,Confirmatory,1825848.0,
417,188199,3,3,,103167911,681,Unspecified,,,,,Maximal cAMP production in rat striatal homogenates.,Other,3761308.0,
418,188331,3,3,,103167911,681,Unspecified,,,,,In vitro Inhibitory activity against prolactin release in anterior pituitary from adult female rats(Charles Rivers Labs) at a concentration of 2*10e-8M,Other,6834384.0,
419,188339,3,3,,103167911,681,Unspecified,,,,,"In vitro Inhibitory activity against prolactin release in anterior pituitary from adult female rats(Charles Rivers Labs), at a concentration of 2*10e-7M",Other,6834384.0,
420,189179,3,3,,103167911,681,Unspecified,,,,,Central dopaminergic activity against contralateral rotation(500) in lesioned rats (ic) in 2 h,Other,7069713.0,
421,189190,4,3,,103167911,681,Unspecified,,,,,Central dopaminergic activity was determined by testing compound for its ability to produce contralateral rotation in lesioned rat after ip administration,Other,7411552.0,
422,189317,5,1,,103167911,681,Unspecified,,,,,Compound was tested for its CNS activity in vivo in SNx rats with 6-hydroxydopamine induced lesions after ic administration,Other,2878077.0,
423,189508,3,3,,103167911,681,Unspecified,,,,,Contralateral rotation produced by intrastriatal injection in rats with unilateral 6-hydroxydopamine-induced lesions of the substantia nigra at 1 nmol; turns/5 min,Other,7252978.0,
424,189510,3,3,,103167911,681,Unspecified,,,,,Contralateral rotation produced by intrastriatal injection in rats with unilateral 6-hydroxydopamine-induced lesions of the substantia nigra at 10 nmol; turns/5 min,Other,7252978.0,
425,189512,3,3,,103167911,681,Unspecified,,,,,Contralateral rotation produced by intrastriatal injection in rats with unilateral 6-hydroxydopamine-induced lesions of the substantia nigra at 3 nmol; turns/5 min,Other,7252978.0,
426,191797,4,3,,103167911,681,Unspecified,,,,,Ability to stimulate the production of cyclic AMP by rat retinal adenylate cyclase at a concentration of 0.1 uM,Other,3309317.0,
427,191798,4,3,,103167911,681,Unspecified,,,,,Ability to stimulate the production of cyclic AMP by rat retinal adenylate cyclase at a concentration of 10 uM,Other,3309317.0,
428,191799,4,3,,103167911,681,Unspecified,,,,,Ability to stimulate the production of cyclic AMP by rat retinal adenylate cyclase at a concentration of 1 uM,Other,3309317.0,
429,192165,3,3,,103167911,681,Unspecified,,,,,In vitro weight change in anterior pituitary after the administration of the compound,Other,6834384.0,
430,193183,3,3,,103167911,681,Unspecified,,,,,"Stimulation of cAMP production in homogenates of corpus striatum from rat brain, at a concentration of 50 uM.",Other,6682147.0,
431,195878,6,2,,103167911,681,Active,,,0.028999999999999998,IC50,Compound concentration required to reduce specific binding of tritiated dopamine to rat brain striatal membrane by 50 % was reported,Confirmatory,7252978.0,
432,195880,3,5,,103167911,681,Unspecified,,,,,Maximal degree of inhibition at 1 uM concentration was determined from displacement of [3H]dopamine binding to rat brain striatal membrane,Other,7252978.0,
433,196240,3,3,,103167911,681,Unspecified,,,,,Compound was evaluated for the stimulation of rat retinal adenylate cyclase at 0.1 uM dose,Other,2956423.0,
434,196241,3,3,,103167911,681,Unspecified,,,,,Compound was evaluated for the stimulation of rat retinal adenylate cyclase at 1.0 uM dose,Other,2956423.0,
435,196242,3,3,,103167911,681,Unspecified,,,,,Compound was evaluated for the stimulation of rat retinal adenylate cyclase at 10.0 uM dose,Other,2956423.0,
436,196243,3,3,,103167911,681,Unspecified,,,,,Compound was evaluated for the stimulation of rat retinal adenylate cyclase at 100.0 uM dose,Other,2956423.0,
437,196426,3,4,,103167911,681,Unspecified,,,,,Effect on cAMP synthesis in rat striatal membranes as increase above basal value at a concentration of 10 uM,Other,7830274.0,
438,196428,8,8,,103167911,681,Active,118211.0,29238.0,0.0021,IC50,Inhibitory concentration for half-maximal displacement of 1.0 nM [3H]ADTN specific binding from rat striatal membranes using 10E-5 sulpiride,Confirmatory,7200145.0,
439,196428,8,8,,103167911,681,Active,118229.0,24316.0,0.0021,IC50,Inhibitory concentration for half-maximal displacement of 1.0 nM [3H]ADTN specific binding from rat striatal membranes using 10E-5 sulpiride,Confirmatory,7200145.0,
440,196428,8,8,,103167911,681,Active,118251.0,25195.0,0.0021,IC50,Inhibitory concentration for half-maximal displacement of 1.0 nM [3H]ADTN specific binding from rat striatal membranes using 10E-5 sulpiride,Confirmatory,7200145.0,
441,196428,8,8,,103167911,681,Active,6226851.0,25432.0,0.0021,IC50,Inhibitory concentration for half-maximal displacement of 1.0 nM [3H]ADTN specific binding from rat striatal membranes using 10E-5 sulpiride,Confirmatory,7200145.0,
442,196428,8,8,,103167911,681,Active,47117674.0,24318.0,0.0021,IC50,Inhibitory concentration for half-maximal displacement of 1.0 nM [3H]ADTN specific binding from rat striatal membranes using 10E-5 sulpiride,Confirmatory,7200145.0,
443,196429,8,8,,103167911,681,Active,118211.0,29238.0,0.002,IC50,Inhibitory concentration half-maximal displacement of 1.0 nM [3H]NPA specific binding from rat striatal membranes using 10e-5 (+/-)ADTN,Confirmatory,7200145.0,
444,196429,8,8,,103167911,681,Active,118229.0,24316.0,0.002,IC50,Inhibitory concentration half-maximal displacement of 1.0 nM [3H]NPA specific binding from rat striatal membranes using 10e-5 (+/-)ADTN,Confirmatory,7200145.0,
445,196429,8,8,,103167911,681,Active,118251.0,25195.0,0.002,IC50,Inhibitory concentration half-maximal displacement of 1.0 nM [3H]NPA specific binding from rat striatal membranes using 10e-5 (+/-)ADTN,Confirmatory,7200145.0,
446,196429,8,8,,103167911,681,Active,6226851.0,25432.0,0.002,IC50,Inhibitory concentration half-maximal displacement of 1.0 nM [3H]NPA specific binding from rat striatal membranes using 10e-5 (+/-)ADTN,Confirmatory,7200145.0,
447,196429,8,8,,103167911,681,Active,47117674.0,24318.0,0.002,IC50,Inhibitory concentration half-maximal displacement of 1.0 nM [3H]NPA specific binding from rat striatal membranes using 10e-5 (+/-)ADTN,Confirmatory,7200145.0,
448,196435,4,3,,103167911,681,Active,,,1.4369999999999998,Ki,Inhibition constant on radiolabeled [125 I] FIDA1 binding to rat striatal membranes,Confirmatory,8093734.0,
449,196436,4,3,,103167911,681,Active,,,5.268,Ki,Inhibition constant on radiolabeled [125 I] FIDA2 binding to rat striatal membranes,Confirmatory,8093734.0,
450,196584,3,3,,103167911,681,Unspecified,,,,,Evaluated for the maximum stimulation of adenylate cyclase in rat striatal tissue with respect to the maximum stimulation caused by dopamine,Other,8568818.0,
451,196588,3,5,,103167911,681,Unspecified,,,,,Specific binding of dopamine to rat striatal tissue was determined by measuring the displacement of 2 nM [3H]dopamine by unlabeled dopamine at 1 uM,Other,7252978.0,
452,196590,3,4,,103167911,681,Unspecified,,,,,Ability to inhibit the K+-induced release of [3H]acetylcholine in dopamine depleted striatal slices at 10 uM,Other,3806598.0,
453,196594,3,4,,103167911,681,Unspecified,,,,,Ability to inhibit the K+-induced release of [3H]acetylcholine in normal striatal slices at 0.3 uM,Other,3806598.0,
454,196595,3,4,,103167911,681,Unspecified,,,,,Ability to inhibit the K+-induced release of [3H]acetylcholine in normal striatal slices at 1 uM,Other,3806598.0,
455,196596,3,4,,103167911,681,Unspecified,,,,,Ability to inhibit the K+-induced release of [3H]acetylcholine in normal striatal slices at 10 uM,Other,3806598.0,
456,196598,3,3,,103167911,681,Unspecified,,,,,Ability to inhibit the K+-induced release of [3H]Acetylcholine in normal striatal slices at 3 uM,Other,3806598.0,
457,196599,3,4,,103167911,681,Unspecified,,,,,Ability to inhibit the K+-induced release of [3H]acetylcholine in normal striatal slices at 30 uM,Other,3806598.0,
458,204084,12,2,,103167911,681,Unspecified,400630.0,6532.0,1100.0,Ki,Displacement of [125I]RT155 binding in HEK cells expressing human SERT,Confirmatory,14592523.0,
459,215613,3,3,,103167911,681,Unspecified,,,,,Dissociation constant against a series of agonists of membranes of the turkey erythrocyte containing mainly Beta adrenergic receptor was determined,Other,7154001.0,
460,218803,3,9,,103167911,681,Unspecified,,,,,Alpha-2 adrenergic receptor activity in guinea pig right atrium,Other,,
461,219797,9,2,,103167911,681,Active,,,0.057999999999999996,Ki,Binding of [3H]clonidine to alpha-2-adrenergic receptor of rat cerebral cortical membranes,Confirmatory,10780918.0,
462,220051,6,3,,103167911,681,Active,,,3.5,EC50,Effective concentration that gives maximal stimulation of cyclic AMP production over the concentration range tested.,Confirmatory,6317860.0,
463,220082,3,4,,103167911,681,Unspecified,,,,,Growth inhibition of YT-nu cell lines at 1.0 mM concentration,Other,6788955.0,
464,226638,3,3,,103167911,681,Unspecified,,,,,Hill coefficient value.,Other,8098771.0,
465,227266,3,3,,103167911,681,Unspecified,,,,,Percentage increase in contractile force was determined by the effect of DMI(desmethylimipramine) at a dosage of 200 ug/kg administered intravenously,Other,7277389.0,
466,227718,7,1,,103167911,681,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
467,228505,3,3,,103167911,681,Unspecified,,,,,Tested for dopamine-sensitive adenylate cyclase stimulation expressed as %DA stimulation at 50 uM,Other,2886663.0,
468,228912,8,1,,103167911,681,Active,,,3.5,ED50,Tested for dopamine-sensitive adenylate cyclase stimulation expressed as ED50,Confirmatory,2886663.0,
469,230953,3,8,,103167911,681,Unspecified,,,,,Ratio of binding to dopamine D2A low/D2A high receptors,Other,10465538.0,
470,232373,4,7,,103167911,681,Unspecified,,,,,Ratio of D2-D3 like receptor to D4 like receptor,Other,11206464.0,
471,232501,3,3,,103167911,681,Unspecified,,,,,Selectivity ratio of Compound as ratio of ED15 relative to iliac vascular resistance(IVR) ED30,Other,7069713.0,
472,232735,3,4,,103167911,681,Unspecified,,,,,Selectivity ratio of compound as ED15 relative to heart rate(HR) ED20,Other,7069713.0,
473,232736,3,4,,103167911,681,Unspecified,,,,,Selectivity ratio of compound as ratio of ED15 relative to mean arterial blood pressure(MABP) ED20,Other,7069713.0,
474,232917,3,7,,103167911,681,Unspecified,,,,,Selectivity index was determined by division of the IC50 for the D-1 receptor by that for the D-2 receptor,Other,1975274.0,
475,233472,3,9,,103167911,681,Unspecified,118206.0,1813.0,,,Hill coefficient for [3H]-Raclopride binding for high and low affinity binding to dopamine D2 receptor,Other,10465538.0,
476,234665,3,3,,103167911,681,Unspecified,,,,,"Renal vasodilator activity was measured between ED20, heart rate (HR) test, and ED15 RVR.",Other,7411552.0,
477,234666,3,4,,103167911,681,Unspecified,,,,,"Renal vasodilator activity was measured between ED20, measure of mean arterial blood pressure (MABP) test, and ED15 RVR.",Other,7411552.0,
478,234667,3,3,,103167911,681,Unspecified,,,,,"Renal vasodilator activity was measured between ED30, measure in iliac vascular resistance (IVR) test, and ED15 RVR",Other,7411552.0,
479,239294,9,2,,103167911,681,Active,,,2.44,Ki,Inhibitory constant for [3H]SCH-23390 binding to Dopamine receptor D1-like of porcine striatal membranes,Confirmatory,15801855.0,
480,239344,9,2,,103167911,681,Active,,,3.31,Ki,Inhibitory constant for [3H]YM-09151-2 binding to Dopamine receptor D2-like in porcine striatal membranes,Confirmatory,15801855.0,
481,252337,7,1,,103167911,681,Unspecified,,,,,Amount of cAMP level in rat neostriatal membranes after incubation at 1 uM,Other,15801855.0,
482,252338,7,1,,103167911,681,Unspecified,,,,,Amount of cAMP level in rat neostriatal membranes after incubation at 10 uM,Other,15801855.0,
483,252339,7,1,,103167911,681,Unspecified,,,,,Amount of cAMP level in rat neostriatal membranes after incubation at 100 uM,Other,15801855.0,
484,252343,7,1,,103167911,681,Unspecified,,,,,Amount of cGMP level in rat neostriatal membranes after incubation at 10 uM,Other,15801855.0,
485,252344,7,1,,103167911,681,Unspecified,,,,,Amount of cGMP level in rat neostriatal membranes after incubation at 0.1 uM,Other,15801855.0,
486,252345,7,1,,103167911,681,Unspecified,,,,,Amount of cGMP level in rat neostriatal membranes after incubation at 1.0 uM,Other,15801855.0,
487,263688,5,8,,103167911,681,Unspecified,401235.0,7299.0,,,Inhibitory activity against tyrosinase at 100uM,Other,16442796.0,
488,268620,7,1,,103167911,681,Active,115449.0,759.0,,,Activation of human recombinant CA1 by CO2 hydrase assay,Other,16730978.0,
489,268621,7,1,,103167911,681,Active,115456.0,760.0,,,Activation of human recombinant CA2 by CO2 hydrase assay,Other,16730978.0,
490,268622,7,1,,103167911,681,Active,30580372.0,71934.0,,,Activation of mouse recombinant CA13 by CO2 hydrase method,Other,16730978.0,
491,272392,8,5,,103167911,681,Inconclusive,1706296.0,100144487.0,,Ki,Displacement of [3H]SCH-23390 from dopamine D1-like receptor in porcine striata homogenate,Confirmatory,17154515.0,
492,272393,7,1,,103167911,681,Inconclusive,,,,Ki,Displacement of [3H]spiperone from dopamine D2-like receptor in porcine striata homogenate,Confirmatory,17154515.0,
493,272394,5,6,,103167911,681,Active,118228.0,1812.0,0.12,EC50,Activity at human dopamine D1 receptor expressed in HEK293 cells assessed as stimulation of cAMP production,Confirmatory,17154515.0,
494,272395,4,10,,103167911,681,Active,118228.0,1812.0,,,Intrinsic activity at human dopamine D1 receptor expressed in HEK293 cells assessed as stimulation of cAMP production relative to dopamine,Other,17154515.0,
495,272396,9,2,,103167911,681,Active,47117674.0,24318.0,0.005,EC50,Activity at rat dopamine D2L receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production,Confirmatory,17154515.0,
496,272397,4,10,,103167911,681,Active,47117674.0,24318.0,,,Intrinsic activity at rat dopamine D2L receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production relative to dopamine,Other,17154515.0,
497,272398,5,6,,103167911,681,Active,1345939.0,1815.0,0.01,EC50,Activity at human dopamine D4.4 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production,Confirmatory,17154515.0,
498,272399,4,11,,103167911,681,Active,1345939.0,1815.0,,,Intrinsic activity at human dopamine D4.4 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production relative to dopamine,Other,17154515.0,
499,273097,3,9,,103167911,681,Unspecified,2501336.0,8639.0,,,Activity of human SSAO measured as hydrogen peroxide production at 1 mM relative to benzylamine oxidation,Other,17034126.0,
500,273098,3,9,,103167911,681,Unspecified,5902787.0,11754.0,,,Activity of mouse SSAO measured as hydrogen peroxide production at 100 uM relative to benzylamine oxidation,Other,17034126.0,
501,274437,5,6,,103167911,681,Active,1345939.0,1815.0,0.0022,EC50,Agonist activity at human D4.4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR,Confirmatory,17149874.0,
502,274441,4,7,,103167911,681,Active,,,0.0027,EC50,Agonist activity at ferret D4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR,Confirmatory,17149874.0,
503,274442,5,6,,103167911,681,Active,6226851.0,25432.0,0.0024,EC50,Agonist activity at rat D4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR,Confirmatory,17149874.0,
504,274443,7,6,,103167911,681,Active,118206.0,1813.0,,Ki,Agonist activity at human D2 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR,Confirmatory,17149874.0,
505,274444,4,6,,103167911,681,Active,,,0.008,EC50,Agonist activity at ferret D2 receptor in HEK293 cells coexpressing Galphaqo5 by FLIPR,Confirmatory,17149874.0,
506,274445,5,6,,103167911,681,Active,47117674.0,24318.0,0.0011,EC50,Agonist activity at rat D2 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR,Confirmatory,17149874.0,
507,291061,7,1,,103167911,681,Active,115449.0,759.0,,,Activation of human recombinant CA1 by CO2 hydrase assay,Other,17540561.0,
508,291063,7,1,,103167911,681,Active,115456.0,760.0,,,Activation of human recombinant CA2 by CO2 hydrase assay,Other,17540561.0,
509,291065,7,1,,103167911,681,Active,1168744.0,766.0,,,Activation of human recombinant CA7 by CO2 hydrase assay,Other,17540561.0,
510,291067,7,1,,103167911,681,Active,8928036.0,23632.0,,,Activation of of human recombinant CA14 by CO2 hydrase assay,Other,17540561.0,
511,305776,7,1,,103167911,681,Active,461680.0,763.0,,,Activation of human recombinant carbonic anhydrase 5A by stopped-flow CO2 hydrase method,Other,17174092.0,
512,305777,7,1,,103167911,681,Active,8928041.0,11238.0,,,Activation of human recombinant carbonic anhydrase 5B by stopped-flow CO2 hydrase method,Other,17174092.0,
513,307896,7,1,,103167911,681,Active,115449.0,759.0,,,Activation of human recombinant CA1 by stopped flow CO2 hydrase method,Other,17499996.0,
514,307897,7,1,,103167911,681,Active,115456.0,760.0,,,Activation of human recombinant CA2 by stopped flow CO2 hydrase method,Other,17499996.0,
515,307898,7,1,,103167911,681,Active,116241278.0,765.0,,,Activation of human recombinant CA6 by stopped flow CO2 hydrase method,Other,17499996.0,
516,312284,4,3,,103167911,681,Unspecified,,,,,Selectivity for human D3 receptor over human D2L receptor,Other,18072730.0,
517,312285,9,1,,103167911,681,Active,118206.0,1813.0,0.209,EC50,Agonist activity at human cloned dopamine D2L receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,Confirmatory,18072730.0,
518,312287,9,1,,103167911,681,Active,1169206.0,1814.0,0.00853,EC50,Agonist activity at human cloned dopamine D3 receptor expressed in AtT-20 cells assessed as stimulation of [35S]GTP-gamma-S binding,Confirmatory,18072730.0,
519,318343,7,1,,103167911,681,Active,115449.0,759.0,,,Activation of human recombinant CA1 by stopped-flow CO2 hydration method,Other,18294854.0,
520,318344,7,1,,103167911,681,Active,115456.0,760.0,,,Activation of human recombinant CA2 by stopped-flow CO2 hydration method,Other,18294854.0,
521,318345,7,1,,103167911,681,Active,83300925.0,768.0,,,Activation of human recombinant CA9 catalytic domain by stopped-flow CO2 hydration method,Other,18294854.0,
522,318346,7,1,,103167911,681,Active,5915866.0,771.0,,,Activation of human recombinant CA12 catalytic domain by stopped-flow CO2 hydration method,Other,18294854.0,
523,319298,5,6,,103167911,681,Active,118228.0,1812.0,0.035,EC50,Agonist activity at human recombinant dopamine D1 receptor expressed in CHO cells assessed as stimulation of cAMP production,Confirmatory,18313303.0,
524,319299,5,6,,103167911,681,Active,118206.0,1813.0,0.043,EC50,Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP production,Confirmatory,18313303.0,
525,319300,3,10,,103167911,681,Unspecified,118228.0,1812.0,,,Intrinsic activity at human recombinant dopamine D1 receptor expressed in CHO cells assessed as stimulation of cAMP production,Other,18313303.0,
526,319301,3,10,,103167911,681,Unspecified,118206.0,1813.0,,,Intrinsic activity at human dopamine D2 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP production,Other,18313303.0,
527,359909,9,5,,103167911,681,Active,128613.0,24898.0,0.2,IC50,Inhibition of dopamine transporter-mediated [3H]dopamine uptake in Wistar rat striatal synaptosomes by liquid scintillation spectrometry,Confirmatory,8676127.0,
528,359910,3,6,,103167911,681,Unspecified,,,,,Ratio of IC50 for rat striatum dopamine D1 receptor to IC50 for Wistar rat striatal synaptosomes dopamine transporter-mediated [3H]dopamine uptake,Other,8676127.0,
529,359911,3,6,,103167911,681,Unspecified,,,,,Ratio of IC50 for rat striatum dopamine D2 receptor to IC50 for Wistar rat striatal synaptosomes dopamine transporter-mediated [3H]dopamine uptake,Other,8676127.0,
530,361979,8,1,,103167911,681,Unspecified,,,,,Membrane permeability by PAMPA,Other,18666771.0,
531,361980,4,3,,103167911,681,Unspecified,,,,,Membrane permeability assessed as passive transport after 4 hrs by PAMPA,Other,18666771.0,
532,361981,7,1,,103167911,681,Unspecified,,,,,Membrane permeability by PAMPA in presence of 20% 1-propanol,Other,18666771.0,
533,361982,3,3,,103167911,681,Unspecified,,,,,Membrane permeability assessed as passive transport after 4 hrs by PAMPA in presence of 20% 1-propanol,Other,18666771.0,
534,365827,7,1,,103167911,681,Active,115449.0,759.0,,,Activation of human recombinant CA1 at 10 uM by stopped-flow CO2 hydration method,Other,18627905.0,
535,365828,7,1,,103167911,681,Active,115456.0,760.0,,,Activation of human recombinant CA2 at 10 uM by stopped-flow CO2 hydration method,Other,18627905.0,
536,365829,7,1,,103167911,681,Active,134047703.0,761.0,,,Activation of human recombinant CA3 at 10 uM by stopped-flow CO2 hydration method,Other,18627905.0,
537,365830,7,1,,103167911,681,Active,115465.0,762.0,,,Activation of human recombinant truncated CA4 at 10 uM by stopped-flow CO2 hydration method,Other,18627905.0,
538,375786,7,1,,103167911,681,Active,115465.0,762.0,,,Activation of human recombinant carbonic anhydrase 4 lacking 20 amino terminal residues by stopped-flow CO2 hydrase method,Other,19464888.0,
539,375787,7,1,,103167911,681,Active,30580362.0,80733.0,,,Activation of membrane associated mouse recombinant carbonic anhydrase 15 isoform by stopped-flow CO2 hydrase method,Other,19464888.0,
540,384698,9,1,,103167911,681,Active,118206.0,1813.0,0.209,EC50,Agonist activity at human dopamine D2L receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,Confirmatory,18410082.0,
541,384700,9,1,,103167911,681,Active,1169206.0,1814.0,0.00853,EC50,Agonist activity at human dopamine D3 receptor expressed in mouse ATt-20 cells assessed as stimulation of [35S]GTPgammaS binding,Confirmatory,18410082.0,
542,384702,3,4,,103167911,681,Unspecified,,,,,Selectivity for human dopamine D3 receptor over human dopamine D2L receptor by [35S]GTPgammaS binding assay,Other,18410082.0,
543,386623,4,8,,103167911,681,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
544,388667,8,5,,103167911,681,Active,118206.0,1813.0,0.45,Ki,Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells,Confirmatory,18834111.0,
545,388668,8,5,,103167911,681,Active,118206.0,1813.0,0.36,Ki,Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells,Confirmatory,18834111.0,
546,388669,8,5,,103167911,681,Active,1169206.0,1814.0,0.24,Ki,Displacement of [3H]spiperone from human D3 receptor expressed in CHO cells,Confirmatory,18834111.0,
547,388670,8,5,,103167911,681,Active,1345939.0,1815.0,0.0062,Ki,Displacement of [3H]spiperone from human D4 receptor expressed in CHO cells,Confirmatory,18834111.0,
548,388686,8,5,,103167911,681,Active,1169206.0,1814.0,0.07200000000000001,Ki,Displacement of [3H]spiperone from human wild type D3 receptor expressed in human HEK293 cells,Confirmatory,18834111.0,
549,388687,4,5,,103167911,681,Active,,,1.1,Ki,Displacement of [3H]spiperone from human D3 D3.32E mutant receptor expressed in human HEK293 cells,Confirmatory,18834111.0,
550,388688,3,3,,103167911,681,Unspecified,,,,,Selectivity ratio of Ki for human wild type D3 receptor over Ki for human D3 D3.32E mutant receptor,Other,18834111.0,
551,388689,4,5,,103167911,681,Unspecified,,,80.0,Ki,Displacement of [3H]spiperone from human D3 F6.51W mutant receptor expressed in human HEK293 cells,Confirmatory,18834111.0,
552,388690,3,3,,103167911,681,Unspecified,,,,,Selectivity ratio of Ki for human wild type D3 receptor over Ki for human D3 F6.51W mutant receptor,Other,18834111.0,
553,409954,4,9,,103167911,681,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
554,409956,4,9,,103167911,681,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
555,409984,7,1,,103167911,681,Active,115449.0,759.0,,,Activation of human recombinant CA1 by stopped-flow CO2 hydrase assay,Other,18930395.0,
556,409986,7,1,,103167911,681,Active,115456.0,760.0,,,Activation of human recombinant CA2 by stopped-flow CO2 hydrase assay,Other,18930395.0,
557,409988,7,1,,103167911,681,Unspecified,,,,,Activation of Methanobacterium thermoautotrophicum beta-class CA by stopped-flow CO2 hydrase assay,Other,18930395.0,
558,409990,7,1,,103167911,681,Unspecified,,,,,Activation of Methanosarcina thermophila Zinc(2)-derived gamma-class CA by stopped-flow CO2 hydrase assay,Other,18930395.0,
559,409992,7,1,,103167911,681,Active,,,,,Activation of Methanosarcina thermophila cobalt(2)-derived gamma-class CA by stopped-flow CO2 hydrase assay,Other,18930395.0,
560,409993,7,1,,103167911,681,Active,134047703.0,761.0,,,Activation of human recombinant CA3 by stopped-flow CO2 hydrase assay,Other,18930395.0,
561,414329,7,1,,103167911,681,Active,115456.0,760.0,,,Activation of human recombinant CA2 by stopped-flow CO2 hydrase method,Other,19231177.0,
562,414330,7,1,,103167911,681,Unspecified,,,,,Activation of Methanothermobacter thermautotrophicus recombinant Cab by stopped-flow CO2 hydrase method,Other,19231177.0,
563,414331,7,1,,103167911,681,Active,1709238.0,855692.0,,,Activation of yeast recombinant CA by stopped-flow CO2 hydrase method,Other,19231177.0,
564,425418,9,1,,103167911,681,Active,118206.0,1813.0,0.209,EC50,Activity at human dopamine D2L receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,Confirmatory,19427222.0,
565,425420,9,1,,103167911,681,Active,1169206.0,1814.0,0.00853,EC50,Activity at human dopamine D3 receptor expressed in AtT cells assessed as stimulation of [35S]GTPgammaS binding,Confirmatory,19427222.0,
566,425422,3,4,,103167911,681,Unspecified,,,,,Selectivity ratio of EC50 for human dopamine D2L receptor to EC50 human dopamine D3 receptor by [35S]GTPgammaS binding assay,Other,19427222.0,
567,426242,12,2,,103167911,681,Unspecified,296439450.0,154.0,64.56,Kd,Binding affinity to human adrenergic beta2 receptor,Confirmatory,19168263.0,
568,427139,8,5,,103167911,681,Active,47117674.0,24318.0,0.19699999999999998,Ki,Displacement of [3H]raclopride from rat dopamine D2short receptor expressed in CHO-K1 cells by liquid scintillation counting,Confirmatory,19454369.0,
569,427140,9,1,,103167911,681,Active,47117674.0,24318.0,1.425,EC50,Agonist activity at rat dopamine D2short receptor expressed in CHO-K1 cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting,Confirmatory,19454369.0,
570,427225,7,1,,103167911,681,Active,,,0.124,Ki,Displacement of [3H]SCH23390 from dopamine D1 receptor expressed in Ltk deficient fibroblast cells by liquid scintillation counting,Confirmatory,19454369.0,
571,427226,3,3,,103167911,681,Unspecified,,,,,"Selectivity index, ratio of Ki for rat dopamine D2short receptor to Ki for dopamine D1 receptor",Other,19454369.0,
572,429528,7,1,,103167911,681,Unspecified,6686057.0,,,,Binding affinity to Mushroom tyrosinase assessed as compound turnover by HPLC analysis,Other,19386398.0,
573,446400,8,1,,103167911,681,Active,118206.0,1813.0,0.209,EC50,Agonist activity at human dopamine D2L receptor expressed in CHO cells assessed as stimulation of [35S]GTPgamma binding,Confirmatory,20038106.0,
574,446402,8,1,,103167911,681,Active,1169206.0,1814.0,0.00853,EC50,Agonist activity at human dopamine D3 receptor expressed in mouse AtT-20 cells assessed as stimulation of [35S]GTPgamma binding,Confirmatory,20038106.0,
575,446404,3,4,,103167911,681,Unspecified,,,,,"Selectivity index, ratio of EC50 for human dopamine D2L receptor to EC50 for human dopamine D3 receptor by [35S]GTPgamma binding assay",Other,20038106.0,
576,455986,3,5,,103167911,681,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
577,456547,3,7,,103167911,681,Unspecified,,,,,Inhibition of DAT PDSP analysis,Other,19962901.0,
578,458632,7,5,,103167911,681,Active,118206.0,1813.0,2.1,Ki,Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells,Confirmatory,20155917.0,
579,458633,8,5,,103167911,681,Active,118206.0,1813.0,0.0029,Ki,Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells,Confirmatory,20155917.0,
580,458634,3,9,,103167911,681,Unspecified,118206.0,1813.0,,,Selectivity ratio of Ki for human dopamine D2 receptor at low affinity state to Ki for human dopamine D2 receptor at high affinity state,Other,20155917.0,
581,458635,3,5,,103167911,681,Unspecified,,,,,Activity at dopamine D2L receptor expressed in HEK293 cells coexpressing Galphaqi5 assessed as maximal efficacy relative to control,Other,20155917.0,
582,458784,3,10,,103167911,681,Active,74656605.0,3636621.0,,,Activation of Candida albicans beta-carbonic anhydrase Nce103 by stopped flow CO2 hydration assay,Other,20061162.0,
583,458787,3,3,,103167911,681,Active,,,,,Activation of Cryptococcus neoformans beta-carbonic anhydrase Can2 by stopped flow CO2 hydration assay,Other,20061162.0,
584,461562,8,1,,103167911,681,Active,118206.0,1813.0,0.209,EC50,Agonist activity at human dopamine D2 receptor expressed in CHO cells by [35S]GTPgammaS binding assay,Confirmatory,20146482.0,
585,461563,8,1,,103167911,681,Active,1169206.0,1814.0,0.00476,EC50,Agonist activity at human dopamine D3 receptor expressed in CHO cells by [35S]GTPgammaS binding assay,Confirmatory,20146482.0,
586,461566,3,3,,103167911,681,Unspecified,,,,,Selectivity ratio of EC50 for human dopamine D2 receptor to EC50 for human dopamine D3 receptor,Other,20146482.0,
587,462829,3,9,,103167911,681,Active,115449.0,759.0,,,Activation of human recombinant CA1 by stopped flow CO2 hydration assay,Other,20176489.0,
588,462830,3,9,,103167911,681,Active,115456.0,760.0,,,Activation of human recombinant CA2by stopped flow CO2 hydration assay,Other,20176489.0,
589,462831,3,9,,103167911,681,Active,116241278.0,765.0,,,Activation of human full length CA6 by stopped flow CO2 hydration assay,Other,20176489.0,
590,462832,3,3,,103167911,681,Unspecified,,,,,Activation of Stylophora pistillata carbonic anhydrase STPCA by stopped flow CO2 hydration assay,Other,20176489.0,
591,463106,1,2,,90341661,681,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
592,464319,3,9,,103167911,681,Active,115456.0,760.0,,,Activation of human recombinant carbonic anhydrase isoenzyme 2 by stopped flow CO2 hydration method,Other,20129782.0,
593,464320,3,7,,103167911,681,Unspecified,,,,,Activation of archaea Methanobacterium thermoautotrophicum recombinant carbonic anhydrase by stopped flow CO2 hydration method,Other,20129782.0,
594,464321,3,9,,103167911,681,Active,1709238.0,855692.0,,,Activation of Saccharomyces cerevisiae recombinant Nce103p by stopped flow CO2 hydration method,Other,20129782.0,
595,464322,3,9,,103167911,681,Active,74610182.0,,,,Activation of Candida glabrata recombinant carbonic anhydrase by stopped flow CO2 hydration method,Other,20129782.0,
596,475504,3,3,,103167911,681,Inactive,,,,,Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins,Other,19640715.0,
597,475505,3,3,,103167911,681,Inactive,,,,,Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins,Other,19640715.0,
598,485290,1,1,,26750067,681,Inconclusive,20150581.0,,0.4467,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
599,485290,1,1,,26753787,681,Inconclusive,20150581.0,,1.2589,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
600,485295,1,2,,90341661,681,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
601,485297,1,1,,90341661,681,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
602,485298,1,1,,90341661,681,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
603,485313,1,2,,90341661,681,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
604,485342,1,2,,90341661,681,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
605,485345,1,2,,90341661,681,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
606,485366,1,2,,90341661,681,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
607,485368,1,2,,90341661,681,Inconclusive,72386991.0,3656265.0,30.1313,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
608,488772,1,1,,90341661,681,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
609,488773,1,2,,90341661,681,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
610,488816,1,1,,90341661,681,Active,4758356.0,2237.0,0.8437,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
611,488837,1,1,,90341661,681,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
612,488949,1,2,,90341661,681,Active,41055989.0,54737.0,1.0621,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
613,488953,1,1,,90341661,681,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
614,488978,1,1,,90341661,681,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
615,488981,1,1,,90341661,681,Active,4503383.0,1812.0,0.2512,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
616,488982,1,1,,90341661,681,Inactive,4503383.0,1812.0,0.08199999999999999,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
617,488983,1,1,,90341661,681,Active,4503383.0,1812.0,0.1,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
618,493017,1,1,,103857981,681,Unspecified,,1813.0,,,Wombat Data for BeliefDocking,Other,1671414.0,
619,493106,1,1,,90341661,681,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
620,493107,1,1,,90341661,681,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
621,493153,1,1,,90341661,681,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
622,493153,1,1,,90341661,681,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
623,493164,1,2,,90341661,681,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
624,493164,1,2,,90341661,681,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
625,493164,1,2,,90341661,681,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
626,496817,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
627,496818,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
628,496819,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
629,496820,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
630,496821,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
631,496823,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
632,496824,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
633,496825,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
634,496826,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
635,496827,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
636,496828,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
637,496829,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
638,496830,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
639,496831,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
640,496832,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
641,497005,4,2,,103167911,681,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
642,502879,3,6,,103167911,681,Unspecified,118228.0,1812.0,,EC50,Agonist activity at human D1 receptor assessed as cAMP accumulation,Confirmatory,20709559.0,
643,503832,2,6,,103167911,681,Active,,,,,Partial agonist activity at adrenergic alpha2A receptor expressed in HEK293 cells coexpressing yellow fluorescent and cyan fluorescent protein assessed as effect on kinetics of receptor conformational change by FRET assay,Other,16407989.0,
644,504327,1,1,,90341661,681,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
645,504332,1,1,,90341661,681,Active,168985070.0,,8.9125,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
646,504536,1,1,,90341661,681,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
647,504547,1,1,,90341661,681,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
648,504548,1,2,,90341661,681,Inconclusive,157877932.0,5655980.0,23.9341,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
649,504749,1,3,,26753787,681,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
650,504749,1,3,,104171172,681,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
651,504749,1,3,1.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
652,504749,1,3,2.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
653,504749,1,3,3.0,104171172,681,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
654,504749,1,3,4.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
655,504749,1,3,5.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
656,504749,1,3,6.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
657,504749,1,3,7.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
658,504749,1,3,8.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
659,504749,1,3,9.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
660,504749,1,3,10.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
661,504749,1,3,11.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
662,504749,1,3,12.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
663,504749,1,3,13.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
664,504749,1,3,14.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
665,504749,1,3,15.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
666,504749,1,3,16.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
667,504749,1,3,17.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
668,504749,1,3,18.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
669,504749,1,3,19.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
670,504749,1,3,20.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
671,504749,1,3,21.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
672,504749,1,3,22.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
673,504749,1,3,23.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
674,504749,1,3,24.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
675,504749,1,3,25.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
676,504749,1,3,26.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
677,504749,1,3,27.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
678,504749,1,3,28.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
679,504749,1,3,29.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
680,504749,1,3,30.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
681,504749,1,3,31.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
682,504749,1,3,32.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
683,504749,1,3,33.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
684,504749,1,3,34.0,26753787,681,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
685,504749,1,3,35.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
686,504749,1,3,36.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
687,504749,1,3,37.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
688,504749,1,3,38.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
689,504749,1,3,39.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
690,504749,1,3,40.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
691,504749,1,3,41.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
692,504749,1,3,42.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
693,504749,1,3,43.0,26753787,681,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
694,504749,1,3,44.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
695,504749,1,3,45.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
696,504749,1,3,46.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
697,504749,1,3,47.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
698,504749,1,3,48.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
699,504749,1,3,49.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
700,504749,1,3,50.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
701,504749,1,3,51.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
702,504749,1,3,52.0,26753787,681,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
703,504749,1,3,53.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
704,504749,1,3,54.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
705,504749,1,3,55.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
706,504749,1,3,56.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
707,504749,1,3,57.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
708,504749,1,3,58.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
709,504749,1,3,59.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
710,504749,1,3,60.0,104171172,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
711,504749,1,3,61.0,26753787,681,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
712,504810,1,2,,90341661,681,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
713,504812,1,2,,90341661,681,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
714,504832,1,1,,104171172,681,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
715,504834,1,1,,104171172,681,Inconclusive,,,16.9441,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
716,504836,1,2,,90341661,681,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
717,504845,1,1,,90341661,681,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
718,504845,1,1,,104171172,681,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
719,504847,1,1,,90341661,681,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
720,504847,1,1,,104171172,681,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
721,504865,1,1,,90341661,681,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
722,504865,1,1,,104171172,681,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
723,513146,4,2,,103167911,681,Unspecified,,,251.42,Ki,Binding affinity to human beta-2 adrenergic receptor delta 5-C271 mutant expressed in Spodoptera frugiperda Sf9 cells,Confirmatory,16799554.0,
724,513151,2,4,,103167911,681,Active,,,,,Agonist activity at human biamane labelled beta-2 adrenergic receptor delta 5-C271/Trp135 mutant assessed as stimulation of [35S]GTPgammaS binding [35S]GTPgammaS binding assay,Other,16799554.0,
725,513152,2,3,,103167911,681,Unspecified,,,,,Partial agonist activity at human biamane labelled beta-2 adrenergic receptor delta 5-C271/Trp135 mutant assessed as bimane response by fluorescence spectroscopy,Other,16799554.0,
726,513153,2,3,,103167911,681,Unspecified,,,,,Agonist activity at human biamane labelled beta-2 adrenergic receptor delta 5-C271/Trp135 mutant assessed as bimane response by fluorescence spectroscopy,Other,16799554.0,
727,513154,4,2,,103167911,681,Unspecified,,,234.9,Ki,Binding affinity to human beta-2 adrenergic receptor delta 5-C271/W135 mutant expressed in Spodoptera frugiperda Sf9 cells,Confirmatory,16799554.0,
728,513741,7,1,,103167911,681,Active,118206.0,1813.0,0.209,EC50,Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,Confirmatory,20605099.0,
729,513742,7,1,,103167911,681,Active,1169206.0,1814.0,0.00476,EC50,Agonist activity at human dopamine D3 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,Confirmatory,20605099.0,
730,513743,2,3,,103167911,681,Unspecified,,,,,Selectivity ratio of EC50 for human dopamine D2 receptor to EC50 for human dopamine D3 receptor,Other,20605099.0,
731,513744,2,10,,103167911,681,Unspecified,118206.0,1813.0,,,Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding relative to dopamine,Other,20605099.0,
732,513745,2,10,,103167911,681,Unspecified,1169206.0,1814.0,,,Agonist activity at human dopamine D3 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding relative to dopamine,Other,20605099.0,
733,515605,4,2,,103167911,681,Active,,,3.9,Ki,Displacement of [3H]YM-09-151-2 from D2-like receptor in pig striatal membrane,Confirmatory,20801048.0,
734,515606,4,3,,103167911,681,Active,,,4.8,EC50,Agonist activity at D2-like receptor in pig striatal membrane assessed as [35S]GTPgammaS binding,Confirmatory,20801048.0,
735,515607,2,4,,103167911,681,Unspecified,,,,,Intrinsic activity at dopamine D2-like receptor in pig striatal membrane assessed as [35S]GTPgammaS binding relative to control,Other,20801048.0,
736,515608,4,3,,103167911,681,Inconclusive,,,,Ki,Displacement of [3H]2BFI from I2 imidazoline binding site in rat brain membrane,Confirmatory,20801048.0,
737,515609,4,3,,103167911,681,Inconclusive,,,,Ki,Displacement of [3H]RX821002 from alpha2 adrenergic receptor in rat brain membrane,Confirmatory,20801048.0,
738,515612,2,3,,103167911,681,Active,,,0.00133,Kd,Displacement of [3H]SCH23390 from dopamine D1-like receptor pig striatal membrane,Confirmatory,20801048.0,
739,540256,1,2,,90341661,681,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
740,540256,1,2,,104171172,681,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
741,540276,1,2,,11111282,681,Inconclusive,420597.0,,18.3564,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
742,540276,1,2,,26750067,681,Inconclusive,420597.0,,18.3564,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
743,540276,1,2,,26753786,681,Inconclusive,420597.0,,18.3564,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
744,540276,1,2,,26753787,681,Inconclusive,420597.0,,18.3564,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
745,540276,1,2,,50107800,681,Inconclusive,420597.0,,18.3564,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
746,540276,1,2,,57288369,681,Inconclusive,420597.0,,18.3564,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
747,540276,1,2,,90341661,681,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
748,540276,1,2,,104171172,681,Inconclusive,420597.0,,28.0702,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
749,548956,4,2,,103167911,681,Unspecified,,,100.0,IC50,Inhibition of soybean lipoxygenase,Confirmatory,21041094.0,
750,548959,3,5,,103167911,681,Unspecified,,,,,Antioxidant activity against AAPH-induced lipid peroxidation assessed as inhibition of conjugated diene hydroperoxide production at 0.1 mM by UV spectrophotometry,Other,21041094.0,
751,548960,1,4,,103167911,681,Unspecified,,,,,Antioxidant activity of the compound assessed as reducing activity of DPPH at 0.1 mM after 20 mins,Other,21041094.0,
752,548961,1,4,,103167911,681,Unspecified,,,,,Antioxidant activity of the compound assessed as reducing activity of DPPH at 0.1 mM after 60 mins,Other,21041094.0,
753,548963,2,4,,103167911,681,Unspecified,,,,,"Antiinflammatory activity in Fisher rat assessed as inhibition of carrageenan-induced paw oedema at 0.01 mmol/kg, po measured after 3.5 hrs",Other,21041094.0,
754,588209,2,3,,103167911,681,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
755,588210,2,4,,103167911,681,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
756,588211,2,3,,103167911,681,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
757,588212,2,3,,103167911,681,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
758,588213,2,3,,103167911,681,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
759,588349,1,1,,90341661,681,Inconclusive,,,31.6228,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
760,588378,1,1,,90341661,681,Inconclusive,171543895.0,6311.0,22.3872,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
761,588453,1,1,,90341661,681,Inconclusive,8659577.0,58819.0,14.1254,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
762,588453,1,1,,124880337,681,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
763,588456,1,1,,90341661,681,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
764,588456,1,1,,124880337,681,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
765,588579,1,1,,90341661,681,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
766,588579,1,1,,104171172,681,Inconclusive,7705344.0,51426.0,8.9125,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
767,588579,1,1,,124880336,681,Inconclusive,7705344.0,51426.0,39.8107,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
768,588579,1,1,,124880337,681,Inconclusive,7705344.0,51426.0,89.1251,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
769,588590,1,1,,124880337,681,Inconclusive,154350220.0,11201.0,89.1251,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
770,588795,1,1,,90341661,681,Active,4758356.0,2237.0,0.8437,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
771,588795,1,1,,124880337,681,Inconclusive,4758356.0,2237.0,89.1251,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
772,588834,2,1,,26753787,681,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
773,588855,1,1,,124880337,681,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
774,588856,1,1,,124880337,681,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
775,589057,1,10,,103167911,681,Unspecified,313104286.0,6817.0,,,Major substrate of human cytosolic sulfotransferase SULT1A1,Other,,
776,589059,1,11,,103167911,681,Unspecified,678019022.0,6818.0,,,Major substrate of human cytosolic sulfotransferase SULT1A3,Other,,
777,589060,1,10,,103167911,681,Unspecified,57013032.0,27284.0,,,Major substrate of human cytosolic sulfotransferase SULT1B1,Other,,
778,592681,1,4,,103167911,681,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
779,602310,1,2,,124880337,681,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
780,602332,1,1,,90341661,681,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
781,602332,1,1,,104171172,681,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
782,602332,1,1,,124880336,681,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
783,602332,1,1,,124880337,681,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
784,624030,1,2,,104171172,681,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
785,624031,1,2,,104171172,681,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
786,624032,1,2,,104171172,681,Active,8393992.0,24660.0,8.0875,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
787,624044,1,2,,104171172,681,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
788,624146,1,1,,90341661,681,Inactive,71051501.0,2744.0,0.4467,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
789,624147,1,1,,90341661,681,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
790,624148,1,2,,90341661,681,Inconclusive,1724069.0,2740.0,7.3078,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
791,624149,1,1,,90341661,681,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
792,624170,1,1,,104171172,681,Inactive,71051501.0,2744.0,22.3872,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
793,624172,1,1,,104171172,681,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
794,624173,1,3,,104171172,681,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
795,624178,1,1,,124880337,681,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
796,624202,1,1,,124880337,681,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
797,624263,1,1,,124880336,681,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
798,624263,1,1,,124880336,681,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
799,624263,1,1,,124880337,681,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
800,624263,1,1,,124880337,681,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
801,624296,1,1,,26753787,681,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
802,624296,1,1,,104171172,681,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
803,624297,1,1,,26753787,681,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
804,624297,1,1,,104171172,681,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
805,624414,1,1,,124880337,681,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
806,624455,1,1,,90341661,681,Active,299681.0,1812.0,0.0517,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
807,624606,1,9,,103167911,681,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
808,624608,3,2,,103167911,681,Unspecified,136731.0,54657.0,,,Specific activity of expressed human recombinant UGT1A4,Other,10836148.0,
809,624610,1,9,,103167911,681,Unspecified,30173486.0,54577.0,,,Specific activity of expressed human recombinant UGT1A7,Other,10836148.0,
810,624613,1,9,,103167911,681,Unspecified,29839636.0,54575.0,,,Specific activity of expressed human recombinant UGT1A10,Other,10836148.0,
811,624616,1,8,,103167911,681,Unspecified,332278237.0,7366.0,,,Specific activity of expressed human recombinant UGT2B15,Other,10836148.0,
812,624619,3,2,,103167911,681,Unspecified,136727.0,7364.0,,,Specific activity of expressed human recombinant UGT2B7,Other,10836148.0,
813,625279,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
814,625280,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
815,625281,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
816,625282,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
817,625283,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
818,625284,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
819,625285,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
820,625286,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
821,625287,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
822,625288,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
823,625289,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
824,625290,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
825,625291,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
826,625292,1,3,,103167911,681,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
827,651631,4,1,,144203718,681,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
828,651632,4,1,,144203718,681,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
829,651633,4,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
830,651634,4,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
831,651635,1,3,,90341661,681,Inconclusive,171543895.0,6311.0,31.6228,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
832,651965,1,1,,124880337,681,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
833,652048,1,2,,144203718,681,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
834,652051,1,1,,144203718,681,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
835,652106,1,1,,90341661,681,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
836,652106,1,1,,124880337,681,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
837,675146,5,5,,103167911,681,Active,118228.0,1812.0,12.0,Ki,Displacement of [3H]SCH23390 from human D1 receptor expressed in HEK293 cells,Confirmatory,22846798.0,
838,675147,5,5,,103167911,681,Active,118206.0,1813.0,2.1,Ki,Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells,Confirmatory,22846798.0,
839,675148,5,5,,103167911,681,Active,1169206.0,1814.0,0.015,Ki,Displacement of [3H]raclopride from human D3 receptor expressed in HEK293 cells,Confirmatory,22846798.0,
840,675149,1,2,,103167911,681,Unspecified,,,,,"Selectivity index, ratio of Ki for human D2L receptor to Ki for human D1 receptor",Other,22846798.0,
841,675150,1,2,,103167911,681,Unspecified,,,,,"Selectivity index, ratio of Ki for human D3 receptor to Ki for human D1 receptor",Other,22846798.0,
842,675151,1,2,,103167911,681,Unspecified,,,,,"Selectivity index, ratio of Ki for human D3 receptor to Ki for human D2L receptor",Other,22846798.0,
843,678784,3,6,,103167911,681,Unspecified,24212062.0,29504.0,384.0,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT3-expressing HRPE cells,Confirmatory,9830022.0,
844,678817,2,7,,103167911,681,Unspecified,81872095.0,24904.0,19.4,Km,TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes,Confirmatory,8898084.0,
845,679157,2,7,,103167911,681,Unspecified,313104182.0,6582.0,390.0,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,9687576.0,
846,679315,2,7,,103167911,681,Unspecified,81872095.0,24904.0,51.0,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,8898084.0,
847,679500,2,7,,103167911,681,Unspecified,313104182.0,6582.0,520.0,Km,TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes,Confirmatory,9687576.0,
848,680326,2,7,,103167911,681,Unspecified,24212062.0,29504.0,,Km,TP_TRANSPORTER: uptake in OCT3-expressing HRPE cells,Confirmatory,9830022.0,
849,680366,2,7,,103167911,681,Unspecified,313104182.0,6582.0,330.0,Km,TP_TRANSPORTER: uptake in OCT2-expressing HEK293 cells,Confirmatory,9687576.0,
850,680543,1,7,,103167911,681,Unspecified,8928277.0,20520.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.01 uM, Dapamine: 5000 uM) in OCTN2-expressing HEK293 cells",Other,11160873.0,
851,681117,3,6,,103167911,681,Unspecified,313104181.0,6580.0,,IC50,TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells,Confirmatory,12606755.0,
852,681368,3,6,,103167911,681,Unspecified,81872789.0,29503.0,347.0,Ki,TP_TRANSPORTER: inhibition of TEA uptake in OCT2-expressing MDCK cells,Confirmatory,11758759.0,
853,681375,3,6,,103167911,681,Unspecified,81872095.0,24904.0,603.0,Ki,TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing MDCK cells,Confirmatory,11758759.0,
854,681565,2,7,,103167911,681,Unspecified,81872789.0,29503.0,2100.0,Km,TP_TRANSPORTER: uptake in OCT2-expressing HEK293 cells,Confirmatory,9812985.0,
855,681591,3,6,,103167911,681,Unspecified,81872789.0,29503.0,2300.0,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT2-expressing HRPE cells,Confirmatory,9830022.0,
856,681601,1,7,,103167911,681,Unspecified,81872095.0,24904.0,,,TP_TRANSPORTER: uptake in OCT1-expressing HEK293 cells,Other,9776363.0,
857,681627,2,7,,103167911,681,Unspecified,81872789.0,29503.0,2300.0,Km,TP_TRANSPORTER: uptake in OCT2-expressing HEK293 cells,Confirmatory,9933568.0,
858,681702,1,7,,103167911,681,Unspecified,8928242.0,29726.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Dopamine: 2500 uM) in OCTN2-expressing HRPE cells",Other,10454528.0,
859,681943,1,7,,103167911,681,Unspecified,313104181.0,6580.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Dopamine: 5000 uM) in OCT1-expressing HeLa cells",Other,9655880.0,
860,681992,1,7,,103167911,681,Unspecified,313104182.0,6582.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Dopamine: 1000 uM) in OCT2A-expressing HEK293 cells",Other,12089365.0,
861,681993,1,7,,103167911,681,Unspecified,313104182.0,6582.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Dopamine: 1000 uM) in OCT2-expressing HEK293 cells",Other,12089365.0,
862,682029,3,6,,103167911,681,Unspecified,24212062.0,29504.0,62.0,IC50,TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in OCT3-expressing HRPE cells,Confirmatory,9830022.0,
863,686978,1,1,,124880336,681,Active,79154014.0,55775.0,5.1735,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
864,686978,1,1,,124880337,681,Inconclusive,79154014.0,55775.0,35.4813,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
865,686978,1,1,,144203718,681,Inconclusive,79154014.0,55775.0,29.8554,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
866,686979,1,1,,124880336,681,Active,79154014.0,55775.0,4.1095,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
867,686979,1,1,,124880337,681,Inconclusive,79154014.0,55775.0,31.6228,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
868,686979,1,1,,144203718,681,Inconclusive,79154014.0,55775.0,18.8375,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
869,688847,1,2,,103167911,681,Unspecified,,,,,"Octanol-phosphate buffered saline partition coefficient, log K of the compound",Other,22047697.0,
870,690845,4,1,,103167911,681,Active,118206.0,1813.0,0.22699999999999998,EC50,Agonist activity at human cloned dopamine D2 receptor expressed in CHO cells by [35S]GTPgammaS binding assay,Confirmatory,22642365.0,
871,690847,4,1,,103167911,681,Active,1169206.0,1814.0,0.00857,EC50,Agonist activity at human cloned dopamine D3 receptor expressed in CHO cells by [35S]GTPgammaS binding assay,Confirmatory,22642365.0,
872,690849,1,2,,103167911,681,Unspecified,,,,,Selectivity ratio of EC50 for human cloned dopamine D2 receptor to EC50 for human cloned dopamine D3 receptor,Other,22642365.0,
873,691713,1,7,,103167911,681,Active,115449.0,759.0,,,Activity of human recombinant CA1 cytosolic isoform after 15 mins by phenol red staining based stopped flow CO2 hydration assay,Other,22999416.0,
874,691714,1,7,,103167911,681,Active,115456.0,760.0,,,Activity of human recombinant CA2 cytosolic isoform after 15 mins by phenol red staining based stopped flow CO2 hydration assay,Other,22999416.0,
875,691715,1,2,,103167911,681,Active,,,,,Activity of Sulfurihydrogenibium yellowstonense YO3AOP1 recombinant CA expressed in Escherichia coli BL21(DE3) after 15 mins by phenol red staining based stopped flow CO2 hydration assay,Other,22999416.0,
876,709654,1,7,,103167911,681,Unspecified,1169206.0,1814.0,,,Agonist activity at human dopamine D3 receptor expressed in CHOp cells assessed as stimulation of mitogenesis incubated for 24 hrs by [3H]thymidine incorporation assay relative to quinpirole,Other,23134120.0,
877,709655,2,6,,103167911,681,Active,1169206.0,1814.0,0.0061,EC50,Agonist activity at human dopamine D3 receptor expressed in CHOp cells assessed as stimulation of mitogenesis incubated for 24 hrs by [3H]thymidine incorporation assay,Confirmatory,23134120.0,
878,709657,1,7,,103167911,681,Unspecified,118206.0,1813.0,,,Agonist activity at human dopamine D2 receptor expressed in CHOp cells assessed as stimulation of mitogenesis incubated for 24 hrs by [3H]thymidine incorporation assay relative to quinpirole,Other,23134120.0,
879,709658,2,6,,103167911,681,Active,118206.0,1813.0,0.065,EC50,Agonist activity at human dopamine D2 receptor expressed in CHOp cells assessed as stimulation of mitogenesis incubated for 24 hrs by [3H]thymidine incorporation assay,Confirmatory,23134120.0,
880,709659,3,5,,103167911,681,Active,118206.0,1813.0,0.42200000000000004,Ki,Displacement of [3H]YM-09151-2 from human dopamine D2 receptor expressed in CHOp cells,Confirmatory,23134120.0,
881,709660,3,5,,103167911,681,Active,1169206.0,1814.0,0.02,Ki,Displacement of [3H]YM-09151-2 from human dopamine D3 receptor expressed in CHOp cells,Confirmatory,23134120.0,
882,709661,3,5,,103167911,681,Active,118228.0,1812.0,4.47,Ki,Displacement of [3H]SCH-23390 from human dopamine D1 receptor expressed in LHD1 cells,Confirmatory,23134120.0,
883,712280,1,2,,103167911,681,Unspecified,,,,,Selectivity ratio of EC50 for human cloned dopamine D2 receptor to EC50 for human cloned dopamine D3 receptor,Other,23275802.0,
884,712282,4,1,,103167911,681,Active,1169206.0,1814.0,0.0058,EC50,Agonist activity at human cloned dopamine D3 receptor expressed in CHO cells by [35S]GTP gammaS binding assay,Confirmatory,23275802.0,
885,712284,4,1,,103167911,681,Active,118206.0,1813.0,0.24,EC50,Agonist activity at human cloned dopamine D2 receptor expressed in CHO cells by [35S]GTP gammaS binding assay,Confirmatory,23275802.0,
886,720516,2,1,,144203718,681,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
887,720532,1,1,,124880336,681,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
888,720532,1,1,,144203718,681,Inconclusive,420597.0,,28.0702,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
889,720533,1,1,,124880336,681,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
890,720533,1,1,,144203718,681,Inconclusive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
891,720538,1,2,,90341661,681,Inconclusive,220983390.0,410.0,26.8545,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
892,720552,2,1,,144203718,681,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
893,720559,1,2,,90341661,681,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
894,720572,1,2,,90341661,681,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
895,720573,1,2,,90341661,681,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
896,720579,2,1,,124880336,681,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
897,720579,2,1,,124880337,681,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
898,720580,1,1,,124880336,681,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
899,720580,1,1,,124880337,681,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
900,720634,2,1,,144203718,681,Inactive,,,13.3332,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
901,720635,2,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
902,720637,2,1,,144203718,681,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
903,720674,2,2,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
904,720675,2,2,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
905,720678,2,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
906,720679,2,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
907,720680,2,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
908,720681,2,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
909,720682,2,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
910,720683,2,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
911,720684,2,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
912,720685,2,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
913,720686,2,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
914,720687,2,2,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
915,720691,4,1,,144203718,681,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
916,720692,3,1,,144203718,681,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
917,720693,3,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
918,720719,2,1,,144203718,681,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
919,720725,2,1,,144203718,681,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
920,725226,1,2,,103167911,681,Active,,,,,Activation of Sulfurihydrogenibium azorense recombinant alpha carbonic anhydrase by stopped flow CO2 hydrase method,Other,23294703.0,
921,725227,1,2,,103167911,681,Active,,,,,Activation of Sulfurihydrogenibium yellowstonense recombinant CA by stopped flow CO2 hydrase method,Other,23294703.0,
922,725228,1,6,,103167911,681,Active,115449.0,759.0,,,Activation of human recombinant CA1 by stopped flow CO2 hydrase method,Other,23294703.0,
923,725229,1,6,,103167911,681,Active,115456.0,760.0,,,Activation of human recombinant CA2 by stopped flow CO2 hydrase method,Other,23294703.0,
924,725981,1,3,,103167911,681,Unspecified,,,300.0,IC50,Inhibition of CMG2 (40 to 217) C175A and R40C double mutant (unknown origin) interaction to full length PA E733C mutant expressed in Escherichia coli by FRET assay,Confirmatory,23394144.0,
925,733540,1,6,,103167911,681,Inactive,112817.0,25187.0,,,Displacement of [125I]-N-(p-I-Bn)-THAZ from 5HT2C in rat cerebral cortex membrane at 300 uM after 1 hr by scintillation counting analysis,Other,23301527.0,
926,733801,2,5,,103167911,681,Active,1169206.0,1814.0,0.021,Ki,Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells,Confirmatory,23428965.0,
927,733804,2,5,,103167911,681,Active,118206.0,1813.0,0.11,Ki,Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells,Confirmatory,23428965.0,
928,733805,1,2,,103167911,681,Active,,,0.0089,Ki,Displacement of [3H]spiperone from human dopamine D4.4 receptor expressed in CHO cells,Confirmatory,23428965.0,
929,733806,2,5,,103167911,681,Active,118206.0,1813.0,0.19,Ki,Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells,Confirmatory,23428965.0,
930,733807,2,5,,103167911,681,Active,110832828.0,281125.0,0.44,Ki,Displacement of [3H]SCH23390 from dopamine D1 receptor in bovine striatum,Confirmatory,23428965.0,
931,743012,3,1,,144203718,681,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
932,743014,3,1,,144203718,681,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
933,743015,3,1,,144203718,681,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
934,743033,3,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
935,743035,2,1,,144203718,681,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
936,743036,2,1,,144203718,681,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
937,743040,3,1,,144203718,681,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
938,743041,3,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
939,743042,3,1,,144203718,681,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
940,743053,2,1,,144203718,681,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
941,743054,2,1,,144203718,681,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
942,743063,2,1,,144203718,681,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
943,743064,3,1,,144203718,681,Inconclusive,,,37.578,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
944,743065,3,1,,144203718,681,Inconclusive,399498506.0,24831.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
945,743066,3,1,,144203718,681,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
946,743067,2,1,,144203718,681,Inconclusive,399498506.0,24831.0,33.4915,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
947,743069,2,1,,144203718,681,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
948,743074,2,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
949,743075,2,1,,144203718,681,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
950,743077,2,1,,144203718,681,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
951,743078,2,1,,144203718,681,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
952,743079,3,1,,144203718,681,Inconclusive,348019627.0,2099.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
953,743080,3,1,,144203718,681,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
954,743081,3,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
955,743083,3,1,,144203718,681,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
956,743084,3,1,,144203718,681,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
957,743085,3,1,,144203718,681,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
958,743086,3,1,,144203718,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
959,743091,2,1,,144203718,681,Inconclusive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
960,743094,3,1,,144203718,681,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
961,743122,2,1,,144203718,681,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
962,743139,2,1,,144203718,681,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
963,743140,2,1,,144203718,681,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
964,743191,3,1,,170464942,681,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
965,743194,3,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
966,743199,2,1,,170464942,681,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
967,743202,4,1,,170464942,681,Active,20149576.0,4780.0,0.3758,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
968,743203,3,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
969,743205,1,1,,90341661,681,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
970,743205,1,1,,90341661,681,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
971,743206,1,1,,90341661,681,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
972,743206,1,1,,90341661,681,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
973,743207,1,1,,90341661,681,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
974,743207,1,1,,90341661,681,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
975,743209,3,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
976,743210,4,1,,170464942,681,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
977,743211,3,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
978,743212,3,1,,170464942,681,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
979,743213,3,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
980,743215,3,1,,170464942,681,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
981,743217,3,1,,170464942,681,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
982,743218,3,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
983,743219,3,1,,170464942,681,Active,20149576.0,4780.0,0.643034,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
984,743220,3,1,,170464942,681,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
985,743221,3,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
986,743222,3,1,,170464942,681,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
987,743223,3,1,,170464942,681,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
988,743224,3,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
989,743225,3,1,,170464942,681,Inconclusive,,,0.2683,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
990,743226,2,1,,170464942,681,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
991,743227,2,1,,170464942,681,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
992,743228,3,1,,170464942,681,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
993,743239,2,1,,170464942,681,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
994,743240,2,1,,170464942,681,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
995,743241,2,1,,170464942,681,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
996,743242,2,1,,170464942,681,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
997,743244,1,1,,90341661,681,Inconclusive,,,6.3096,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
998,743244,1,1,,144203718,681,Inconclusive,,,35.4813,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
999,743344,1,1,,124880340,681,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
1000,743345,1,1,,124880340,681,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
1001,743346,1,1,,124880340,681,Inactive,,,16.7744,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
1002,743347,1,1,,124880340,681,Inactive,,,0.1188,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
1003,750040,1,1,,103167911,681,Unspecified,,,,,Selectivity ratio of EC50 for human dopamine D2L receptor to EC50 for human dopamine D3 receptor,Other,23623679.0,
1004,750041,1,5,,103167911,681,Unspecified,1169206.0,1814.0,,,Agonist activity at human dopamine D3 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis relative to dopamine,Other,23623679.0,
1005,750042,3,1,,103167911,681,Active,1169206.0,1814.0,0.007640000000000001,EC50,Agonist activity at human dopamine D3 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,Confirmatory,23623679.0,
1006,750043,1,5,,103167911,681,Unspecified,118206.0,1813.0,,,Agonist activity at human dopamine D2L receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis relative to dopamine,Other,23623679.0,
1007,750044,3,1,,103167911,681,Active,118206.0,1813.0,0.22699999999999998,EC50,Agonist activity at human dopamine D2L receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis,Confirmatory,23623679.0,
1008,750640,2,3,,103167911,681,Active,1169206.0,1814.0,0.0018,EC50,Agonist activity at dopamine D3 receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 by FLIPR assay,Confirmatory,23675993.0,
1009,750641,1,5,,103167911,681,Unspecified,1169206.0,1814.0,,,Agonist activity at dopamine D3 receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 at 10 uM by FLIPR assay relative to control,Other,23675993.0,
1010,750644,2,3,,103167911,681,Active,118206.0,1813.0,0.0067,EC50,Agonist activity at dopamine D2 receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 by FLIPR assay,Confirmatory,23675993.0,
1011,750645,1,5,,103167911,681,Unspecified,118206.0,1813.0,,,Agonist activity at dopamine D2 receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 at 10 uM by FLIPR assay relative to control,Other,23675993.0,
1012,756322,1,1,,103167911,681,Unspecified,,,,,Selectivity ratio of Ki for human dopamine D1 receptor to Ki for human dopamine D2L receptor,Other,23727194.0,
1013,756323,1,1,,103167911,681,Unspecified,,,,,Selectivity ratio of Ki for human dopamine D2L receptor to Ki for human dopamine D3 receptor,Other,23727194.0,
1014,756324,2,3,,103167911,681,Active,1169206.0,1814.0,0.015,Ki,Displacement of [3H]raclopride from human dopamine D3 receptor expressed in HEK293 cells by scintillation counting analysis,Confirmatory,23727194.0,
1015,756325,2,3,,103167911,681,Active,118206.0,1813.0,2.1,Ki,Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells by scintillation counting analysis,Confirmatory,23727194.0,
1016,756326,2,3,,103167911,681,Active,118228.0,1812.0,12.0,Ki,Displacement of [3H]SCH23390 from human dopamine D1 receptor expressed in HEK293 cells by scintillation counting analysis,Confirmatory,23727194.0,
1017,1054224,1,1,,103167911,681,Unspecified,,,280.0,Km,Activity at mushroom tyrosinase by Michaelis-Menten plot analysis,Confirmatory,24125877.0,
1018,1054306,2,3,,103167911,681,Active,118206.0,1813.0,,Ki,Displacement of [3H]-NPA from dopamine D2L receptor (unknown origin) expressed in CHO cell membranes,Confirmatory,24138311.0,
1019,1060971,1,1,,103167911,681,Unspecified,,,,,Selectivity ratio of EC50 for human recombinant dopamine D1 receptor to EC50 for human dopamine D2 receptor,Other,24296012.0,
1020,1060973,3,1,,103167911,681,Active,118206.0,1813.0,0.036000000000000004,EC50,Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as increase of forskolin-induced cAMP production after 20 mins,Confirmatory,24296012.0,
1021,1060975,2,3,,103167911,681,Active,118228.0,1812.0,0.039,EC50,Agonist activity at human recombinant dopamine D1 receptor expressed in CHO cells assessed as cAMP production after 20 mins,Confirmatory,24296012.0,
1022,1075445,1,1,,103167911,681,Unspecified,,,,,Selectivity ratio of EC50 for human dopamine D2 receptor to EC50 for human dopamine D3 receptor,Other,24471976.0,
1023,1075447,1,4,,103167911,681,Unspecified,1169206.0,1814.0,,,Agonist activity at human dopamine D3 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding relative to dopamine,Other,24471976.0,
1024,1075448,3,1,,103167911,681,Active,1169206.0,1814.0,0.0106,EC50,Agonist activity at human dopamine D3 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,Confirmatory,24471976.0,
1025,1075449,1,4,,103167911,681,Unspecified,118206.0,1813.0,,,Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding relative to dopamine,Other,24471976.0,
1026,1075450,3,1,,103167911,681,Active,118206.0,1813.0,0.218,EC50,Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding,Confirmatory,24471976.0,
1027,1093077,2,3,,103167911,681,Active,118211.0,29238.0,0.111,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D3 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
1028,1093078,2,3,,103167911,681,Active,118211.0,29238.0,0.124,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
1029,1093079,1,4,,103167911,681,Active,118211.0,29238.0,0.483,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
1030,1093079,1,4,,103167911,681,Active,47117674.0,24318.0,0.483,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
1031,1093080,1,4,,103167911,681,Active,118211.0,29238.0,0.5820000000000001,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
1032,1093080,1,4,,103167911,681,Active,47117674.0,24318.0,0.5820000000000001,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
1033,1093081,2,3,,103167911,681,Active,47117674.0,24318.0,3.14,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D2 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
1034,1093082,2,3,,103167911,681,Active,47117674.0,24318.0,3.26,IC50,Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting,Confirmatory,,
1035,1094238,1,2,,103167911,681,Unspecified,,,,,"Neurotoxicity inRattus norvegicus albino (rat) assessed as motor coordination at 10 mg/kg, ip after 30 min by rotated test",Other,,
1036,1094240,1,2,,103167911,681,Inactive,,,,,"Antiparkinson's activity in Rattus norvegicus albino (rat) assessed as reduction of chlorpromazine-induced catatonia at 10 mg/kg, ip administered 30 min before chlorpromazine challenge measured up to 180 min",Other,,
1037,1117298,1,2,,170464942,681,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
1038,1117304,1,2,,170464942,681,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
1039,1117305,1,2,,170464942,681,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
1040,1117310,1,1,,170464942,681,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
1041,1117312,1,1,,170464942,681,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
1042,1117314,1,1,,170464942,681,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
1043,1117326,1,1,,170464942,681,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
1044,1117329,1,1,,170464942,681,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
1045,1117336,1,1,,170464942,681,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
1046,1117340,1,1,,170464942,681,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
1047,1117341,1,1,,170464942,681,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
1048,1117342,1,1,,170464942,681,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
1049,1117343,1,1,,170464942,681,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
1050,1117346,1,1,,170464942,681,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
1051,1124653,1,1,,103167911,681,Active,,,,,Dopaminergic activity in Sprague-Dawley rat assessed as hyperactivity up to 6.25 to 50 ug administered into nucleus accumbens,Other,571020.0,
1052,1124654,1,1,,103167911,681,Active,,,,,Dopaminergic activity in Sprague-Dawley rat assessed as stereotyped behavior characterized by continous sniffing up to 12.5 to 50 ug administered into nucleus accumbens,Other,571020.0,
1053,1124656,1,1,,103167911,681,Inactive,,,,,Dopaminergic activity in Sprague-Dawley rat assessed as biting behavior up to 50 ug administered into nucleus accumbens,Other,571020.0,
1054,1124657,1,1,,103167911,681,Active,,,,,Dopaminergic activity in Sprague-Dawley rat assessed as locomotor behavior administered into nucleus accumbens measured up to 25 ug from 30 to 45 mins to persisted up to 5 to 6 hrs,Other,571020.0,
1055,1124659,1,1,,103167911,681,Active,,,,,Dopaminergic activity in Sprague-Dawley rat assessed as hyperactivity behavior administered into nucleus caudate-putamen measured up to 25 ug from 30 to 45 mins to persisted up to 5 to 6 hrs,Other,571020.0,
1056,1124662,1,1,,103167911,681,Active,,,,,Dopaminergic activity in Sprague-Dawley rat assessed as hyperactivity 6.25 to 25 ug administered into caudate-putamen,Other,571020.0,
1057,1124663,1,1,,103167911,681,Active,,,,,Dopaminergic activity in Sprague-Dawley rat assessed as hyperactivity 6.25 to 50 ug administered into caudate-putamen,Other,571020.0,
1058,1124664,1,1,,103167911,681,Active,,,,,Dopaminergic activity in Sprague-Dawley rat assessed as stereotypic behavior administered into caudate-putamen measured up to 25 ug from 5 to 15 mins to persisted up to 5 to 6 hrs,Other,571020.0,
1059,1131062,3,2,,103167911,681,Unspecified,,,,,Pressor activity in iv dosed normotensive Sprague-Dawley rat assessed as dose required for increasing systolic blood pressure to 30 mm Hg,Other,533879.0,
1060,1131394,1,1,,103167911,681,Unspecified,,,,,Stereotyped behavior in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as biting behavior treated direct injection into caudate-putamen,Other,556776.0,
1061,1131407,1,1,,103167911,681,Active,,,,,Stereotyped behavior in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as sniffing behavior at 12.5 to 50 mg/kg direct injection into caudate-putamen,Other,556776.0,
1062,1131408,1,1,,103167911,681,Active,,,,,Behavioral responses in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as bilateral response at 6.25 to 25 mg/kg direct injection into caudate-putamen,Other,556776.0,
1063,1131409,1,1,,103167911,681,Active,,,,,Behavioral responses in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as hyperactivity response at 6.25 to 25 mg/kg direct injection into caudate-putamen,Other,556776.0,
1064,1131421,1,1,,103167911,681,Inactive,,,,,Behavioral responses in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as hyperactivity response at 6.25 to 50 mg/kg direct injection into nucleus accumbens,Other,556776.0,
1065,1131422,1,1,,103167911,681,Active,,,,,Stereotyped behavior in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as sniffing behavior at 3.125 to 25 mg/kg direct injection into nucleus accumbens,Other,556776.0,
1066,1131423,1,1,,103167911,681,Inactive,,,,,Stereotyped behavior in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as biting behavior at 12.5 to 100 mg/kg direct injection into nucleus accumbens,Other,556776.0,
1067,1131834,1,1,,103167911,681,Unspecified,,,,,Toxicity in Sprague-Dawley rat assessed as sniffing at 200 ug injection into nucleus accumbens,Other,573798.0,
1068,1132590,1,1,,103167911,681,Unspecified,,,,,Induction of vasodilation in intraarterially dosed anesthetized Mongrel dog at 3 nmol to 0.19 umol,Other,650669.0,
1069,1132592,1,3,,103167911,681,Unspecified,117786.0,81636.0,,,Activation of rat striatal homogenate adenylate cyclase assessed as cAMP level at 100 uM after 2.5 mins relative to control,Other,650669.0,
1070,1132592,1,3,,103167911,681,Unspecified,117787.0,64508.0,,,Activation of rat striatal homogenate adenylate cyclase assessed as cAMP level at 100 uM after 2.5 mins relative to control,Other,650669.0,
1071,1132592,1,3,,103167911,681,Unspecified,117788.0,54223.0,,,Activation of rat striatal homogenate adenylate cyclase assessed as cAMP level at 100 uM after 2.5 mins relative to control,Other,650669.0,
1072,1132592,1,3,,103167911,681,Unspecified,416857.0,25289.0,,,Activation of rat striatal homogenate adenylate cyclase assessed as cAMP level at 100 uM after 2.5 mins relative to control,Other,650669.0,
1073,1132592,1,3,,103167911,681,Unspecified,729243.0,29241.0,,,Activation of rat striatal homogenate adenylate cyclase assessed as cAMP level at 100 uM after 2.5 mins relative to control,Other,650669.0,
1074,1132592,1,3,,103167911,681,Unspecified,2833201.0,64532.0,,,Activation of rat striatal homogenate adenylate cyclase assessed as cAMP level at 100 uM after 2.5 mins relative to control,Other,650669.0,
1075,1132592,1,3,,103167911,681,Unspecified,81900271.0,,,,Activation of rat striatal homogenate adenylate cyclase assessed as cAMP level at 100 uM after 2.5 mins relative to control,Other,650669.0,
1076,1132810,1,1,,103167911,681,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,671451.0,
1077,1132811,1,2,,103167911,681,Unspecified,,,,,Acute pressor activity in iv dosed Sprague-Dawley rat assessed as dose required to increase arterial systolic blood pressure by 30 mmHg,Other,671451.0,
1078,1132813,1,2,,103167911,681,Unspecified,,,,,Acute pressor activity in iv dosed Sprague-Dawley rat assessed as duration of arterial systolic blood pressure by 30 mmHg maintenance,Other,671451.0,
1079,1136412,1,1,,103167911,681,Unspecified,,,,,Displacement of (-)-[3H]alprenolol from adrenergic receptor purified from frog erythrocytes,Other,31486.0,
1080,1153301,3,2,,103167911,681,Active,,,,Ki,Displacement of [3Hprazosin from adrenergic alpha1 receptor in pig cerebral cortex homogenates by competitive binding assay,Confirmatory,24831693.0,
1081,1153304,1,3,,103167911,681,Unspecified,118206.0,1813.0,,,Agonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells co-expressing Galphao1 after 30 mins by [35S]GTPgammaS binding assay relative to quinpirole,Other,24831693.0,
1082,1153305,4,1,,103167911,681,Active,118206.0,1813.0,0.46774,EC50,Agonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells co-expressing Galphai2 after 30 mins by [35S]GTPgammaS binding assay,Confirmatory,24831693.0,
1083,1153306,1,3,,103167911,681,Unspecified,118206.0,1813.0,,,Agonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells co-expressing Galphai2 after 30 mins by [35S]GTPgammaS binding assay relative to quinpirole,Other,24831693.0,
1084,1153307,4,1,,103167911,681,Active,1169206.0,1814.0,0.00933,EC50,Agonist activity at human dopamine D3 receptor transiently expressed in HEK293 cells co-expressing Galphao1 after 30 mins by [35S]GTPgammaS binding assay,Confirmatory,24831693.0,
1085,1153308,1,3,,103167911,681,Unspecified,1169206.0,1814.0,,,Agonist activity at human dopamine D3 receptor transiently expressed in HEK293 cells co-expressing Galphao1 after 30 mins by [35S]GTPgammaS binding assay relative to quinpirole,Other,24831693.0,
1086,1153315,1,3,,103167911,681,Unspecified,118206.0,1813.0,,,Agonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells co-expressing Galphao1 after 30 mins by [35S]GTPgammaS binding assay,Other,24831693.0,
1087,1157847,2,2,,103167911,681,Unspecified,118206.0,1813.0,,EC50,Agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay,Confirmatory,24827597.0,
1088,1157848,1,3,,103167911,681,Unspecified,118206.0,1813.0,,,Ratio of intrinsic efficacy to KA for human D2L receptor expressed in FlpIn CHO cells assessed as inhibition of forskolin-stimulated cAMP production treated for 30 mins by AlphaScreen assay,Other,24827597.0,
1089,1157849,1,3,,103167911,681,Unspecified,118206.0,1813.0,,,Intrinsic activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay,Other,24827597.0,
1090,1157850,1,3,,103167911,681,Unspecified,118206.0,1813.0,,,Ratio of intrinsic efficacy to KA for human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay,Other,24827597.0,
1091,1159509,1,1,,170464942,681,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1092,1159515,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1093,1159516,1,1,,170464942,681,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1094,1159517,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1095,1159518,1,1,,170464942,681,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1096,1159519,1,1,,170464942,681,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1097,1159520,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1098,1159521,1,1,,170464942,681,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1099,1159523,1,1,,170464942,681,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1100,1159524,1,1,,124880336,681,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1101,1159525,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1102,1159526,1,1,,170464942,681,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1103,1159527,1,1,,170464942,681,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1104,1159528,1,1,,170464942,681,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1105,1159529,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1106,1159531,1,1,,170464942,681,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1107,1159551,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1108,1159552,1,1,,170464942,681,Inconclusive,325495463.0,5914.0,4.2163,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1109,1159553,2,1,,170464942,681,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1110,1159555,1,1,,170464942,681,Inconclusive,325495463.0,5914.0,4.21632,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1111,1159580,2,1,,268734530,681,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1112,1159580,2,1,,273002836,681,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1113,1159580,2,1,,277425731,681,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1114,1159607,2,1,,312310266,681,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1115,1159614,1,2,,170464942,681,Inconclusive,22328079.0,2581.0,4.4668,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
1116,1160670,1,2,,103167911,681,Active,300680972.0,390245.0,3.0,IC50,Inhibition of N-terminal His-6-tagged human JMJD2E (1 to 337 residues) expressed in Escherichia coli by MALDI-TOF/MS analysis,Confirmatory,,
1117,1167634,1,1,,103167911,681,Unspecified,,,,,Blood brain permeability of the compound at donor and acceptor by PAMPA assay,Other,25282654.0,
1118,1190185,1,1,,103167911,681,Unspecified,,,,,Permeability of the compound after 16 hrs by PAMPA,Other,25542589.0,
1119,1198140,1,1,,103167911,681,Unspecified,,,,,Permeability of the compound in PBS and EtOH by PAMPA method,Other,25656088.0,
1120,1201746,1,1,,103167911,681,Unspecified,,,,,Permeability of the compound after 16 hrs by PAMPA,Other,25812965.0,
1121,1201747,1,1,,103167911,681,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25812965.0,
1122,1209455,1,2,,103167911,681,Unspecified,262527527.0,8647.0,1000.0,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
1123,1209456,1,2,,103167911,681,Unspecified,12585136.0,83569.0,1000.0,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
1124,1209457,1,1,,103167911,681,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
1125,1215083,1,2,,103167911,681,Unspecified,81872789.0,29503.0,650.0,Km,Binding affinity to rat Oct2 assessed as transporter-mediated drug uptake,Confirmatory,20962061.0,
1126,1224824,1,1,,124880340,681,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
1127,1224825,1,1,,124880340,681,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
1128,1224834,3,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1129,1224835,1,1,,170464942,681,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1130,1224836,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1131,1224837,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1132,1224838,1,1,,170464942,681,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1133,1224839,1,1,,170464942,681,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1134,1224840,3,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1135,1224841,3,1,,170464942,681,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1136,1224842,3,1,,170464942,681,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1137,1224843,1,1,,170464942,681,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1138,1224844,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1139,1224845,1,1,,170464942,681,Inconclusive,344243002.0,100757539.0,24.6554,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1140,1224846,1,1,,170464942,681,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1141,1224847,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1142,1224848,3,1,,170464942,681,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1143,1224849,3,1,,170464942,681,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1144,1224857,2,1,,124880340,681,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1145,1224857,2,1,,170464942,681,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1146,1224859,2,1,,90341661,681,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1147,1224859,2,1,,124880340,681,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1148,1224859,2,1,,170464942,681,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1149,1224863,1,1,,176485036,681,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1150,1224863,1,1,,316920281,681,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1151,1224867,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1152,1224868,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1153,1224869,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1154,1224870,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1155,1224871,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1156,1224872,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1157,1224873,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1158,1224874,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1159,1224875,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1160,1224876,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1161,1224877,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1162,1224878,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1163,1224879,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1164,1224880,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1165,1224881,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1166,1224882,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1167,1224883,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1168,1224884,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1169,1224885,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1170,1224886,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1171,1224887,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1172,1224888,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1173,1224889,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1174,1224890,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1175,1224892,1,1,,170464942,681,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1176,1224893,1,1,,170464942,681,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1177,1224894,1,1,,170464942,681,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1178,1224895,1,1,,170464942,681,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1179,1224896,1,1,,170464942,681,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1180,1257018,1,1,,103167911,681,Inactive,,,,,Antioxidant activity assessed as increase of DPPH free radical scavenging activity by measuring reducing activity at 100 uM after 60 mins by spectrophotometry,Other,26515039.0,
1181,1257019,1,1,,103167911,681,Unspecified,,,,,Antioxidant activity assessed as DPPH free radical scavenging activity by measuring reducing activity at 100 uM after 20 mins by spectrophotometry,Other,26515039.0,
1182,1257020,1,1,,103167911,681,Unspecified,,,,,Antioxidant activity assessed as inhibition of AAPH-induced linoleic acid lipid peroxidation at 100 uM,Other,26515039.0,
1183,1257021,1,1,,103167911,681,Unspecified,,,100.0,IC50,Inhibition of soybean LOX assessed as reduction in conversion of sodium linoleate to 13-hydroperoxylinoleic acid by UV analysis,Confirmatory,26515039.0,
1184,1257023,1,1,,103167911,681,Unspecified,,,,,"Anti-inflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip after 3.5 hrs",Other,26515039.0,
1185,1259241,1,1,,170464942,681,Inconclusive,,,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1186,1259242,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1187,1259243,1,1,,170464942,681,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1188,1259244,1,1,,170464942,681,Inconclusive,348019627.0,2099.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1189,1259247,1,1,,170464942,681,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1190,1259248,1,1,,170464942,681,Inconclusive,348019627.0,2099.0,19.9496,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1191,1259252,1,1,,124880340,681,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
1192,1259253,1,1,,124880340,681,Active,169655958.0,,16.6261,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
1193,1259255,1,1,,124880340,681,Active,169655958.0,,16.6261,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
1194,1259256,1,1,,124880340,681,Active,169655958.0,,1.6626,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
1195,1259310,1,1,,332949612,681,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1196,1259325,1,2,,336954434,681,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
1197,1259344,1,1,,144203718,681,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1198,1259355,1,1,,26753787,681,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1199,1259356,1,1,,144203718,681,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1200,1259364,1,1,,170464942,681,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1201,1259365,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1202,1259366,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1203,1259367,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1204,1259368,1,1,,170464942,681,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1205,1259369,1,1,,170464942,681,Inconclusive,109731339.0,2737.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1206,1259377,1,1,,170464942,681,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1207,1259378,1,1,,170464942,681,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1208,1259379,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1209,1259380,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1210,1259381,1,1,,170464942,681,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1211,1259382,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1212,1259383,1,1,,170464942,681,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1213,1259384,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1214,1259385,1,1,,170464942,681,Inconclusive,119601739.0,7253.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1215,1259386,1,1,,170464942,681,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1216,1259387,1,1,,170464942,681,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1217,1259388,1,1,,170464942,681,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1218,1259390,1,1,,170464942,681,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1219,1259391,1,1,,170464942,681,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1220,1259392,1,1,,170464942,681,Active,109731339.0,2737.0,16.1535,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1221,1259393,1,1,,170464942,681,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1222,1259394,1,1,,170464942,681,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1223,1259395,1,1,,170464942,681,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1224,1259396,1,1,,170464942,681,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1225,1259400,1,1,,170464942,681,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
1226,1259401,1,1,,170464942,681,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1227,1259402,1,1,,170464942,681,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1228,1259403,1,1,,170464942,681,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1229,1259404,1,1,,170464942,681,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1230,1259408,1,1,,363894789,681,Inactive,,,,,GENE-TOX mutagenicity studies,Other,,
1231,1259416,1,2,,340079372,681,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1232,1259421,1,1,,340079372,681,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1233,1259423,1,2,,354804897,681,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1234,1259423,1,2,,354866734,681,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1235,1259423,1,2,,354932088,681,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1236,1259423,1,2,,354959015,681,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1237,1259423,1,2,,354963470,681,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1238,1259423,1,2,,354972027,681,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
